

Ligand bias underlies differential signaling of multiple FGFs via FGFR1

Kelly Karl, Nuala Del Piccolo, Taylor Light, Tanaya Roy, Pooja Dudeja, Vlad-Constantin Ursachi, Bohumil Fafílek, Pavel Krejčí, Kalina Hristova 

Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University, Baltimore MD 21218 • Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic • International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic • Institute of Animal Physiology and Genetics of the CAS, 60200 Brno, Czech Republic

Reviewed Preprint

Revised by authors after peer review.

About eLife's process

Reviewed preprint version 2

August 10, 2023 (this version)

Reviewed preprint version 1

June 6, 2023

Sent for peer review

April 6, 2023

Posted to bioRxiv

April 4, 2023

 https://en.wikipedia.org/wiki/Open_access

 <https://creativecommons.org/licenses/by/4.0/>

Abstract

FGFR1 signals differently in response to the fgf ligands FGF4, FGF8 and FGF9, but the mechanism behind the differential ligand recognition is poorly understood. Here, we use biophysical tools to quantify multiple aspects of FGFR1 signaling in response to the three FGFs: potency, efficacy, bias, ligand-induced oligomerization and downregulation, and conformation of the active FGFR1 dimers. We find that the three ligands exhibit distinctly different potencies and efficacies for inducing signaling responses in cells. We further find that FGF8 is a biased ligand, as compared to FGF4 and FGF9. This bias is evident in the phosphorylation of FGFR1 and associated proteins, as well as in FGFR1-mediated functional responses. Our data suggest that the FGF bias arises due to structural differences in the FGF-FGFR1 dimers, which impact the interactions of the FGFR1 transmembrane helices, leading to differential recruitment and activation of the downstream signaling adaptor FRS2. This study expands the mechanistic understanding of FGF signaling during development and brings the poorly understood concept of receptor tyrosine kinase ligand bias into the spotlight.

eLife assessment

This manuscript describes **useful** data on the mechanisms underlying the activation of the receptor tyrosine kinase FGFR1 and stimulation of intracellular signaling pathways in response to FGF4, FGF8, or FGF9 binding to the extracellular domain of FGFR1. **Solid** quantitative binding experiments are presented to demonstrate that FGF4, FGF8, and FGF9 exhibit distinct binding affinities towards FGFRs.

Introduction

Fibroblast growth factor receptor (FGFR) belongs to the family of receptor tyrosine kinases (RTKs), which signal via lateral dimerization in the plasma membrane to control cell growth, differentiation, motility, and metabolism (1 –3 ). The four known FGFRs (FGFR1–4) are single-pass membrane receptors, with an N-terminal ligand-binding extracellular (EC) region composed of three Ig-like domains, a transmembrane (TM) domain, and an intracellular (IC) region that

contains a juxtamembrane (JM) domain, a kinase domain, and a cytoplasmic tail (4 [↗](#)). The cross-phosphorylation of tyrosines in the activation loop of the FGFRs in the ligand-bound dimers is known to stimulate catalytic activity, resulting in the phosphorylation of secondary intracellular tyrosines, which recruit cytoplasmic effector proteins (5 [↗](#)). These effector proteins, once phosphorylated by FGFRs, trigger downstream signaling cascades that control cell behavior (6 [↗](#), 7 [↗](#)).

The FGFRs signal in response to extracellular ligands with a beta trefoil fold, called fibroblast growth factors (FGFs) (8 [↗](#)). As many as 18 different FGF ligands are known to bind to and trigger distinct cellular responses through a total of seven variants of four FGFRs (FGFR1-4) (9 [↗](#)–11 [↗](#)). The diversity in FGF-FGFR interactions far exceeds that of other RTK systems, reflecting the morphogen role that FGF signaling plays in the development of many tissues and organs. FGFR1 is well known for its critically important role in the development of the skeletal system, and has been implicated in many cancers (12 [↗](#)–16 [↗](#)). One specific example of a developmental process controlled by the FGFR1c is limb bud outgrowth (17 [↗](#), 18 [↗](#)). The limb bud forms early in the developing embryo and consists of mesenchymal cells sheathed in ectoderm. The process starts as the mesenchymal cells begin to proliferate until they create a bulge under the ectodermal cells above. This is followed by the formation of the apical ectodermal ridge (AER) by the cells from the ectoderm, which specifies the proximal-distal axis of the limb, ensuring limb outgrowth (17 [↗](#), 18 [↗](#)). These roles are carried out by several FGF ligands, including FGF4, FGF8, and FGF9, which are produced and secreted by the ectodermal cells in the AER and have similar spatio-temporal expressions. The ligands diffuse into the mesenchymal region adjacent to the AER, and act upon the mesenchymal cells which express the “c” variant of FGFR1 (FGFR1c). This leads to the activation of signaling pathways downstream of FGFR1c, promoting survival and proliferation of the mesenchymal cells.

Experiments involving genetic ablation of FGF4, FGF8 and FGF9 have led to distinct limb malformations (19 [↗](#)). Thus, the actions of these ligands through FGFR1c are different, but the mechanism behind the differential response of FGFR1c to multiple ligands has not been investigated. More broadly, it is not known how a cell recognizes the identities of different FGF ligands, when bound to and signaling through the same FGFR. Here we sought to investigate the molecular mechanism behind differences in FGFR1c signaling in response to FGF4, FGF8, and FGF9.

Results

Differences in FGF-induced activation of the ERK pathway in cultured chondrocytes

To investigate whether FGF4, FGF8 and FGF9 induce differential signaling via FGFR1, we used rat chondrosarcoma (RCS) chondrocytes, a cell line used to model proliferating chondrocytes in developing limb (20 [↗](#)). By western blot, the RCS cells express detectable amounts of both FGFR1 and FGFR2 (**Figure 1A** [↗](#)). While FGFR3 and FGFR4 cannot be detected by western blotting, transcripts for FGFR3 and FGFR4 can be found by qPCR. To create an RCS variant that expresses FGFR1 only, CRISPR/Cas9 was used to disrupt the endogenous, FGFR2, FGFR3 and FGFR4 genes in RCS cells (21 [↗](#)), to generate cells expressing only the endogenous FGFR1 (RCS^{Fgfr1}). As a control, we used CRISPR/Cas9 to disrupt all endogenous *FGFR* genes in RCS cells (**Fig. 1A** [↗](#); RCS Fgfr1-4 null). The RCS^{Fgfr1} cells were treated with FGF4, FGF8 and FGF9 for up to 1h, and activation of the RAS-ERK MAP kinase pathway, which represents the major downstream signaling FGFR module, was monitored by western blot (**Fig. 1B** [↗](#)). FGF4, FGF8 and FGF9 showed significant differences in FGFR1-mediated activation of ERK, with FGF4 inducing the strongest signal, compared to weaker signals detected in cells treated with FGF8 and FGF9. To investigate the dynamics of ERK activation in further detail, we used a genetic reporter of ERK activity. Briefly, the RCS^{Fgfr1} cells

were transfected with the transcriptional reporter pKrox24 (22 [↗](#)), engineered to induce the expression of eGFP upon ERK pathway activation. The pKrox signal was monitored for 48 hours by automated microscopy. Significant differences in pKrox24 transactivation were found, with FGF4 inducing the strongest signal, in both magnitude and duration, compared to FGF9 and FGF8. Significant differences were also observed between FGF8 and FGF9-induced ERK activation (Fig.1C [↗](#)). These experiments showed that the three FGF ligands induce differential activation of ERK in RCS chondrocytes, consistent with the genetic ablation experiments (19 [↗](#)), and prompted studies into the mechanism behind these differences.

Differences in FGF-induced FGFR1 oligomerization

While most RTKs signal as dimers, it has been reported that under some conditions RTKs can form oligomers with different signaling capabilities (23 [↗](#), 24 [↗](#)). Therefore, we considered the possibility that FGF4, FGF8, and FGF9 promote the formation of different types of FGFR1 oligomers in the plasma membrane. We thus assessed the association state of FGFR1, labeled with YFP, using fluorescence intensity fluctuations (FIF) spectrometry. The fluorophores were attached to the C-terminus of FGFR1 via a GGS flexible linker; this attachment has been used before and has been shown to not affect function (25 [↗](#)). The FIF experiments utilized 293T cells stably transfected with FGFR1-YFP.

FIF calculates molecular brightness of the YFP-tagged receptors in small regions of the cell membrane (26 [↗](#)). The molecular brightness, defined as the ratio of the variance of the fluorescence intensity within a membrane region to the mean fluorescence intensity in this region, is known to scale with the oligomer size (27 [↗](#)). The molecular brightness distributions of monomeric (Linker for Activation of T-cells, LAT; gray) (28 [↗](#), 29 [↗](#)) and dimeric controls (TrkA in the presence of 130 nM nerve growth factor, NGF; black) (30 [↗](#)) in 293T cells are shown in **Figure 2A** [↗](#), along with the brightness distribution for FGFR1 in 293T cells stably expressing FGFR1-YFP (red). We found that FGFR1, in the absence of ligand (red line), exists in a monomer/dimer equilibrium, as its brightness distribution is between the distributions of LAT (monomer control) and TrkA in the presence of saturating concentration of NGF (dimer control). The FIF experiments also report on the concentration of the receptors at the cell surface, which we find to be in the range 100-200 FGFR1/ μm^2 in the stable cell line. This concentration is similar to previously reported FGFR expression levels of the order of ~80,000 receptors per cell, corresponding to ~80-100 receptors/ μm^2 (31 [↗](#)).

Next, we performed FIF experiments in the presence of FGF4, FGF8, and FGF9. The FGFs were added at high concentrations (130 nM), which exceed the reported FGF binding constants (in the ~nM range) (32 [↗](#), 33 [↗](#)) such that all FGFR1 receptors are FGF-bound. The brightness distributions in the presence of the FGF are shown in **Figure 2A** [↗](#). We see that the brightness distributions recorded in the presence of FGF8 (green) and FGF9 (blue) overlap with the distribution for the dimer control, while the distribution for FGF4 (orange) appears shifted to higher brightness. In fact, these data fall between the dimer control and the large oligomer control (EphrinA1+ephrinA1-Fc) (24 [↗](#), 34 [↗](#)–36 [↗](#)). This suggests that the average oligomer size may be increased beyond a dimer in the presence of FGF4. We analyzed the likelihood of this possibility using a statistical test. Since the distributions of molecular brightness are log-normal, we analyzed the corresponding log(brightness) distributions which are Gaussian (**Figure 2B** [↗](#)). The parameters of the Gaussian distributions and the standard errors were calculated and used in a Z-test. Results, shown in **Figure 2C** [↗](#), show that there are statistically significant differences ($Z > 2$, (37 [↗](#))) between the FGFR1 brightness distribution in the FGF4 case and the distribution for the dimer control (TrkA+NGF). Likewise, there are statistically significant differences between the FGFR1+FGF4 brightness distribution, on one hand, and the FGFR1+FGF8 and FGFR1+FGF9 brightness distributions, on the other ($Z > 2$). Further, the distributions measured for FGFR1+FGF8




Figure 1.

(A) Expression of FGFR1 and FGFR2 in wildtype RCS cells, RCS *null* for FGFR1-4, and RCS cells expressing only endogenous FGFR1 (RCS^{Fgfr1}). Actin serves as a loading control; n, number of independent experiments. **(B)** RCS^{Fgfr1} cells were treated with FGF4, FGF8 and FGF9 for indicated times and ERK phosphorylation (pErk) was monitored by western blot. Vinculin serves as a loading control. pErk signal was quantified and graphed (right) as relative values compared to the 10' FGF4 stimulation; data show average and SEM of six independent experiments. **(C)** RCS^{Fgfr1} expressing the pKrox(MapERK)d1EGFP reporter were treated with FGF4, FGF8, and FGF9 and pKrox24 transactivation was monitored for 48 hours.




Figure 2

The oligomerization state of FGFR1, as measured by fluorescence intensity fluctuation (FIF) spectrometry. (A) Brightness distributions shown on the linear scale. Brightness scales with the oligomer size. LAT (gray) is a monomer control, TrkA+130 nM NGF (black) is a dimer control. EphA2 bound to ephrinA1-Fc (brown) is an oligomer control. All distributions are scaled to a maximum of 1. (B) Distributions of $\log(\text{brightness})$. Points represent the experimental FIF data, and the solid lines are the best fit Gaussians. (C) Means of the best-fit Gaussians and the standard errors of the mean.

and FGFR1+FGF9 are the same as the dimer control distribution. This analysis demonstrates that while FGF8-bound and FGF9-bound FGFR1 forms dimers, FGF4 binding promotes the formation of higher order FGFR1 oligomers.

Differences in FGFR1 Phosphorylation Dose Response curves

Next, we studied FGFR1 signaling in response to FGF4, FGF8, and FGF9 using quantitative western blotting. In particular, we acquired FGFR1 dose response curves while varying the concentrations of FGF4, FGF8, or FGF9 over a broad range. As we sought mechanistic interpretation of the results, we used the same 293T cell line used in the FIF experiments, since the FGFR1 expression and the FGFR1 oligomer size in the cell line is known.

The cells were incubated with FGFs for 20 minutes at 37°C, after which the cells were lysed, and the lysates were subjected to SDS-PAGE while probing with antibodies recognizing specific phospho-tyrosine motifs. We assessed several “responses”: (i) phosphorylation of Y653/654, the two tyrosines in the activation loop of the FGFR1 kinase that are required for kinase activity ([4](#), [6](#), [38](#), [39](#)); (ii) phosphorylation of Y766 in the kinase tail of FGFR1, which serves as a binding site for PLC γ ([40](#)); (iii) phosphorylation of FRS2, an adaptor protein that is constitutively associated with FGFR1 through interactions that do not involve phosphorylated tyrosines ([41](#), [42](#)); and (iv) phosphorylation of PLC γ which binds to Y766 ([43](#)). In addition, we also blotted for the total expression of FGFR1, thus assaying for ligand-induced FGFR1 downregulation. Typical western blots are shown in **Figure 3A**. The band intensities from at least three independent experiments were quantified and plotted for each response and each ligand concentration in **Figures 3C**. The dose response curves in each panel were placed on a common scale by re-running some of the samples on a common gel, as shown in **Figure 3B**. The protocol to place the dose response curves on a common scale is given in Supplementary Data.

The quantified results are shown in **Figure 3C**, which reveals unexpected differences in the shape of the dose response curves. While FGF8 and FGF9 dose response curves appear sigmoidal when plotted on a semi-log scale, as expected for a rectangular hyperbolic curve (**equation 1**), FGF4 exhibits an increase in phosphorylation up to 2.6 nM, followed by a marked decrease in phosphorylation for all studied responses as the FGF4 concentration is further increased.

What could explain the very unusual FGF4 dose response curves in **Figure 3C**? We first considered the possibility that the shape of the FGF4 dose response is due to strong FGF4-induced FGFR1 degradation at high FGF4 concentrations. Data in **Figure 3C**, however, do not support this view as the effect of FGF4 on FGFR1 downregulation is smaller when compared to the effects of FGF8 and FGF9. Thus, differential ligand-induced FGFR1 degradation cannot explain the shape of the dose response curves.

We next considered the possibility that the shape of the FGF4 dose response curve is due to differential FGFR1 de-phosphorylation kinetics. In particular, we asked whether at high FGF concentration, a fast de-phosphorylation occurs for FGF4-bound FGFR1, while the de-phosphorylation of FGF8-bound and FGF9-bound FGFR1 is slower. As the western blot data were acquired after 20 minutes of stimulation, such differences in kinetics could explain the shape of the dose response. We thus measured Y653/654 phosphorylation via western blotting as a function of time, when 130 nM FGF was added to the cells for a duration of 0, 1, 5, 10, 20, and 60 minutes. The averages of 3 independent experiments are shown in **Figure 4A**, along with the standard errors. We see a quick increase in phosphorylation over time, followed by a decrease which may be due to FGFR1 de-phosphorylation and/or FGFR1 downregulation. Notably, the phosphorylation decrease in response to FGF4 is very similar when compared to the decrease in the presence of FGF9, while the FGF8-induced phosphorylation decrease is smaller. Thus, the FGF4-induced de-phosphorylation kinetics are not fundamentally different when compared to the FGF9 results and cannot provide an explanation for the observed decrease in FGFR1 phosphorylation at high FGF4 concentration.




Figure 3

Activation of FGFR1 and downstream signaling substrates in HEK 293T cells. (A) Sample western blots for Y653/4 FGFR1 phosphorylation and FRS2 phosphorylation in response to FGF4, FGF8, and FGF9. (B) An example blot used for data scaling, where samples with maximum phosphorylation in response to FGF4, FGF8, and FGF9 are rerun on the same gel (C) Dose response curves from the Western blot experiments. The points represent the averaged data, while the solid lines are the best fit rectangular hyperbolic curves. Fit parameters are shown in [Table 1](#).




Figure 4

FGFR1 phosphorylation as a function of time after ligand addition. (A) Phosphorylation time course of Y653/654 at high ligand concentration (130 nM) (B) Phosphorylation time-course of Y653/654 at low ligand concentration (2.6 nM) (C) Phosphorylation time-course of FRS2 at high ligand concentration (130 nM) (D) Phosphorylation time-course of FRS2 at low ligand concentration (2.6 nM)

Another possible explanation for the shape difference in the dose response curves could be that the FGF4-stabilized FGFR1 oligomers, observed in the FIF experiments at high FGF4 concentration (**Figure 2**), are less active than the FGFR1 dimers. To gain further insights into FGF4-induced FGFR1 oligomerization, we performed FIF experiments in the presence of 2.6 nM FGF4, which corresponds to the peak of Y653/654 phosphorylation in the FGF4 dose response curve. The brightness distribution at 2.6 nM FGF4, shown in **Figure 2**, lies between the monomer control and the dimer control. The Z-test analysis shows that the 2.6 nM FGF4 brightness distribution is significantly different from both the monomer and dimer control distributions, as well as from the distribution observed in the presence of high FGF4 concentration. Thus, at low FGF4 concentration, FGFR1 exists primarily in monomeric and dimeric states, while higher FGF4 concentrations (>2.6 nM FGF4) induce the formation of FGFR1 oligomers. The increase in phosphorylation at low FGF4 concentration can therefore be associated with FGFR1 dimers, while the subsequent phosphorylation decrease can be correlated with the appearance of oligomers in addition to dimers. Thus, the assumption that FGFR1 oligomers are less active than FGFR1 dimers can indeed provide an explanation for the observed shape of the FGF4 dose response curves.

Differences in Phosphorylation Potencies and Efficacies, and Demonstration of Ligand Bias

We next analyzed the dose response curves in **Figure 3C** to determine the potencies and the efficacies of FGF4, FGF8 and FGF9. These two parameters were determined as optimal fit parameters in the context of rectangular hyperbolic dose response curves (see **equation 1**), as done in the GPCR literature (44–46). The efficacy (E_{top} in **equation 1**) is the highest possible response that can be achieved for a ligand, typically at high ligand concentration. The potency (EC_{50} in **equation 1**), on the other hand, is the ligand concentration that produces 50% of the maximal possible response for a given ligand. A highly potent ligand will evoke a certain response at low concentrations, while a ligand of lower potency will evoke the same response at much higher concentration.

The fitting of the FGF4 dose response curves presented a particular challenge, as we could only fit the increasing portions of the dose response curves to a rectangular hyperbolic. As described in Materials and Methods, we truncated the data for the fit, including the data in the ascending portions of the curves and taking into account that the average errors in the western blots are 5–10%. In particular, we truncated all dose response curves at the highest ligand concentration that is within 10% of the maximum response value. Under the assumption that the decrease in the FGF4 dose response curve is due to oligomerization, the best-fit FGF4 dose response curves represent the response of the FGFR1 dimers to FGF4.

The best fits for all dose response curves are shown in **Figure 3C** with the solid lines. The best fit values of E_{top} and EC_{50} for all studied responses are shown in **Table 1**. FGF4 exhibits the highest potency, followed by either FGF8 or FGF9, dependent of the particular response. FGF8 exhibits the highest efficacy, followed by either FGF4 or FGF9, dependent of the particular response. In most cases, FGF8 is a full agonist, while FGF9 and FGF4 are partial agonists. However, FGF4 and FGF8 appear to be both full agonists when FRS2 phosphorylation is probed (see **Table 1** and **Figure 3C**).

The results in **Table 1** show that the rank-ordering of the different ligands is different when different responses are probed, which is indicative of ligand bias. “Biased agonism” or ‘ligand bias’ is the ability of different ligands to differentially activate different signaling pathways downstream of the same receptor (47). Ligand bias reflects not just quantitative differences in downstream signaling, but a fundamental difference between the signaling responses to different ligands (48, 49). To determine if bias exists or not, we calculate bias coefficients using **equation 2**. Each bias coefficient, shown in **Table 2**, compares two responses and two ligands

pFGFR			PLCg		
	EC50	Etop		EC50	Etop
FGF4	4.77E-10 ± 0.42E-10	0.95 ± 0.03	FGF4	7.98E-11 ± 2.15E-11	0.80 ± 0.04
FGF8	1.04E-8 ± 0.23E-8	1.11 ± 0.07	FGF8	1.05E-9 ± 0.23E-9	0.99 ± 0.03
FGF9	2.09E-9 ± 0.31E-9	0.70 ± 0.02	FGF9	2.05E-10 ± 0.40E-10	0.62 ± 0.02
p766			pFRS		
	EC50	Etop		EC50	Etop
FGF4	5.84E-10 ± 1.26E-10	0.76 ± 0.05	FGF4	3.42E-10 ± 0.70E-10	0.94 ± 0.06
FGF8	1.42E-8 ± 0.25E-8	1.16 ± 0.07	FGF8	1.62E-9 ± 0.29E-9	0.98 ± 0.03
FGF9	1.94E-9 ± 0.71E-9	0.56 ± 0.05	FGF9	1.65E-9 ± 0.15E-9	0.52 ± 0.01
Downregulation			Proliferation		
	EC50	Etop		EC50	Etop
FGF4	7.34E-10 ± 4.54E-10	0.27 ± 0.04	FGF4	2.59E-12 ± 1.1E-13	0.99 ± 0.00
FGF8	1.39E-8 ± 0.39E-8	0.63 ± 0.05	FGF8	1.60E-9 ± 2.3E-10	1.14 ± 0.04
FGF9	6.80E-9 ± 2.08E-9	0.42 ± 0.02	FGF9	5.89E-11 ± 8.5E-12	0.95 ± 0.00
Collagen Loss					
	EC50	Etop			
FGF4	1.24E-11 ± 2.79E-12	1.02 ± 0.01			
FGF8	8.51E-11 ± 2.86E-11	0.77 ± 0.03			
FGF9	5.67E-11 ± 2.89E-11	0.86 ± 0.06			

Table 1

Best fit parameters for dose response curves in **Figures 3** and **5**. EC50 is the potency of the ligand, and Etop is the efficacy (see **equation 1**).

and reveals whether a response is preferentially engaged by one of the ligands ($\beta \neq 0$) or whether both response are activated similarly by both ligands ($\beta = 0$). We refer to the entire set of coefficients as a “bias map.”

We assessed statistical significance of the differences in bias coefficients for each pair of responses using ANOVA as described in Materials and Methods. The results of the statistical analysis are shown in **Table 2**, where gray shading indicates statistical significance between either FGF4 or FGF9, on one hand, and the reference ligand FGF8, on the other. We see no statistical significance between FGF4 and FGF9 (Supplemental Table S2).

Based on the ANOVA analysis, we conclude that FGF8 is biased towards phosphorylation of FRS2, against phosphorylation of Y653/654 and Y766, and against PLC γ activation, as compared to FGF9. Furthermore, FGF8 is biased towards phosphorylation of FRS2 and against phosphorylation of Y653/654 and Y766, as compared to FGF4.

Phosphorylation time courses cannot explain the existence of ligand bias

Previously, it has been suggested that ligand bias may arise due to differences in the time courses of phosphorylation (50, 51). We therefore sought to compare phosphorylation of the activation loop tyrosines Y653/654 and FRS2 over time. We chose these two particular responses because FGF8 is biased towards FRS2 and against Y653/654 FGFR1 phosphorylation, when compared to FGF4 and FGF9 (**Table 2**). Thus, we complemented the Y653/654 phosphorylation time course in **Figure 4A**, acquired at high concentration (130 nM FGF), with kinetics measurements of Y653/654 phosphorylation at low (2.6 nM) FGF concentration, as well as FRS2 phosphorylation at low (2.6 nM) and high (130 nM ligand) FGF concentrations. Three independent time courses were acquired for each ligand-receptor pair, and the results were averaged. Data, scaled such that the maximal phosphorylation is set to 1, are shown in **Figure 4B-D**.

We observe differences in the time courses of Y653/654 and FRS2 phosphorylation. In the case of FRS2, we always observe fast accumulation of phosphorylated FRS2, which then decreases over time. Such a behavior has been observed for other RTKs and can be explained by the fact that auto-phosphorylation within the RTK dimers/oligomers occurs faster than phosphatase-mediated de-phosphorylation, after which a steady state is established (52, 53). An early maximum in phosphorylation (at 5 minutes) is seen for FRS2 at both low and high FGF concentration, and is very pronounced for high FGF concentration. An early phosphorylation maximum is also observed for Y653/654 FGFR at high FGF concentration, but not at low FGF concentration.

When comparing the time-courses of FGFR1 phosphorylation, in every panel of **Figure 4**, we do not see discernable differences in the time course of FGF8-induced phosphorylation, as compared to FGF4 or FGF9. Thus, the time course of phosphorylation alone cannot identify FGF8 as a biased ligand, when compared to FGF4 or FGF9.

Differences in cellular responses and demonstration of functional bias

Biased signaling manifests itself in different cellular responses, which can be cell-specific (48). We therefore investigated if cells expressing FGFR1 respond differently when stimulated with FGF8 and FGF9, as these two FGFs are biased and their effects at high concentrations can be directly compared as the phosphorylation responses come to a plateau (**Figure 3**). We compared FGFR1 clearance from the plasma membrane due to FGF-induced uptake, cell apoptosis, and cell viability, for the 293T cells used in the western blotting experiments. These cellular responses have been previously reported to occur downstream of FGFR1 activation (7, 54, 55).

β		
	4v8	9v8
pY653/654 vs pY766	-0.07 $\pm$ 0.16	0.05 $\pm$ 0.15
pY653/654 vs pPLCγ	-0.24 $\pm$ 0.18	0.01 $\pm$ 0.14
pY653/654 vs pFRS2	-0.61 $\pm$ 0.16	-0.78 $\pm$ 0.12
pY766 vs pPLCγ	-0.18 $\pm$ 0.19	-0.04 $\pm$ 0.17
pY766 vs pFRS2	-0.54 $\pm$ 0.17	-0.83 $\pm$ 0.16
pPLCγ vs pFRS2	-0.37 $\pm$ 0.20	-0.79 $\pm$ 0.13
pY653/654 vs Downregulation	-0.36 $\pm$ 0.26	-0.36 $\pm$ 0.16
pY766 vs Downregulation	-0.29 $\pm$ 0.27	-0.41 $\pm$ 0.19
pPLCγ vs Downregulation	-0.12 $\pm$ 0.28	-0.37 $\pm$ 0.16
pFRS2 vs Downregulation	0.25 $\pm$ 0.27	0.42 $\pm$ 0.15
Collagen Loss vs Growth Arrest	-1.77 $\pm$ 0.20	-1.13 $\pm$ 0.18

Table 2

Calculated Bias Coefficients using [equation 2](#). Gray shading indicates statistical significance between either FGF4 or FGF9 and the reference ligand FGF8 (see Supplemental Table S2 for p-values).

To study FGFR1 endocytosis, we measured the decrease in FGFR1-YFP concentration in the plasma membrane in response to a 2-minute treatment of 130 nM of FGF8 or FGF9. After fixation, the plasma membranes in contact with the substrate were imaged on a confocal microscope, and the fluorescence intensities for hundreds of cells stimulated with either FGF8, FGF9, or no ligand were recorded. The average fluorescence intensities for the three groups, from three independent experiments, are shown in [Figure 5A](#). We observed a decrease in fluorescence, corresponding to a decrease in plasma membrane concentration of FGFR1-YFP in response to FGF8, as compared to FGF9 and no ligand. This effect was statistically significant by ANOVA ($p < 0.05$). On the other hand, there were no statistically significant differences in FGFR1-YFP membrane concentrations between the FGF9-treated and control groups. These results indicate that FGF8 is more efficient at inducing FGFR1 removal from the plasma membrane immediately after ligand addition, as compared to FGF9. Of note, this result is consistent with the data in [Figure 3C](#), which show that the efficacy of FGF8-induced downregulation, measured in the western blot experiments 20 minutes after ligand addition, was higher than the FGF9 efficacy. However, the total FGFR1 expression is not affected by a 2-minute treatment with ligand ([Figure S1](#)), consistent with the expectation that the FGF8-induced decrease in FGFR1 membrane concentration in [Figure 5A](#) reflects enhanced internalization that precedes degradation.

We next sought to measure and compare the relative amounts of live FGFR1-expressing cells after stimulation with FGF and after six days of starvation, using a MTT assay. The read-out as a function of FGF concentration is shown in [Figure 5B](#), revealing a slight decrease with concentration for both FGF8 and FGF9. Data were fitted to linear functions, and the slopes were compared using a t-test. Results show that there is a significant difference in cell viability when cells are stimulated with FGF8 or FGF9 ($p < 0.015$), and the effects are significant when compared to the case of no FGF.

To monitor the apoptosis of cells exposed to different FGF8 and FGF9 concentrations, we used a commercial kit that measures the combined activity of caspases 3 and 7 (Magic Red Caspase Kit) through an increase in caspase substrate fluorescence. Experiments were conducted at 0, 20, 40, and 100 nM FGF, under starvation conditions, and the results for each set of experiments were scaled such that caspase activity was 1.0 in the absence of FGF. Experiments were repeated at least five times. Data in [Figure 5C](#) show the scaled caspase activity as a function of FGF concentration. We see a significant increase in caspase activity in the case of FGF8, but not FGF9. Data were fitted to linear functions, and the best-fit slopes were compared using a t-test. The difference between the slopes was statistically significant ($p < 0.005$), indicating that FGF8 promotes apoptosis more efficiently than FGF9 in 293T cells.

We thus observe that FGF8 is more efficient than FGF9 at promoting FGFR1 clearance from the plasma membrane, apoptosis, and cell viability under starvation conditions. This is a manifestation of the ligand bias seen upstream.

Since the FGF-induced effects on 293T cell responses were modest, and the dose response curves did not exhibit rectangular hyperbolic shapes to allow bias coefficient calculations, we quantified two well known functional responses of RCS cells to FGF treatment, growth arrest and loss of collagen type 2 expression ([56](#), [57](#)). Collagen 2 amounts were measured using western blotting after 48 hours of treatment with FGFs at varying concentrations ([Figures 5D](#) and [E](#)). Similarly, the growth arrest of RCS^{Fgfr1} cells was determined after 72 hours of stimulation with the three FGFs ([Figure 5F](#)). The dose response curves in [Figures 5E](#) and [5F](#) demonstrate that FGF4, FGF8 and FGF9 have very different effects on the two functional responses that we quantified.

The dose response curves were fitted using [eqn 1](#) and the EC50 and Etop values are reported in [Table 1](#). The three FGFs exhibit different potencies, with FGF4 being the most potent inducer of both responses. The potencies of FGF8 and FGF9 for collagen 2 reduction are similar, but their




Figure 5

Functional FGFR1-mediated responses to different ligands. (A) FGFR1 concentration in the plasma membrane of HEK 293T cells at $t=2$ mins following ligand addition for FGF8, FGF9 and no ligand control. (B) HEK 293T cell viability after ligand exposure and six days of starvation for varying ligand concentrations. (C) Apoptosis of HEK 293T cells under starvation conditions, exposed to varying concentrations of FGF8 and FGF9. Results are summarized in Table S5. (D) $\text{RCS}^{\text{Fgfr1}}$ cells were treated with FGF4, FGF8 and FGF9 for 48 hours, and the levels of collagen type 2 were determined by western blot. Actin serves as a loading control. (E) Dose response curves describing collagen type 2 loss. (F) Dose response curves for growth arrest of $\text{RCS}^{\text{Fgfr1}}$ cells after 72 hours, in response to FGF4, FGF8 and FGF9.

effects on cell proliferation differ significantly. The efficacies in inducing collagen 2 reduction appear different, with FGF4 behaving as full agonist and FGF8 and FGF9 as partial agonists. The efficacies in inducing growth arrest are similar for the three FGFs.

The bias coefficients are reported in **Table 2**. FGF8 is strongly biased towards collagen loss and against growth arrest, when compared to FGF4 and FGF9. The effect is highly significant (Table S2).

Structural determinants behind FGFR1 biased signaling

We sought possible structural determinants behind the observed FGF bias. For GPCRs, it is now well established that different GPCR ligands stabilize different receptor conformations, where each of the conformations has a preference for a subset of downstream signaling molecules (either G proteins or arrestins) (25, 58, 59). We therefore asked if structural differences in the FGF4, FGF8, and FGF9-bound FGFR1 dimers may explain bias for FGF8, as compared to FGF4 and FGF9.

It is known that FRS2 binds to FGFR1 JM domain in a ligand-independent manner (42, 60). It is also believed that the conformation of the JM domain of RTKs is influenced by the conformation of the TM domain dimer in response to ligand binding (59, 61). Further, the FGFR1 TM domain has already been shown to sense the identity of the bound FGF, either FGF1 or FGF2, and adopt a different TM domain dimer conformation (25). We therefore sought to investigate the possibility that the TM domains of FGFR1 dimerize differently when FGF8, as compared to FGF4 and FGF9, is bound to the FGFR1 EC domain.

A Förster resonance energy transfer (FRET)-based methodology has been instrumental in revealing differences in FGFR TM domain dimer conformations in response to FGF binding (25). In these experiments, we monitored differences in the intracellular distances and relative orientation of fluorescent protein reporters when different ligands bind to the EC domain. We used truncated FGFR1 constructs, which contain the entire EC and TM domains of FGFR1 followed by a flexible linker and either mCherry or YFP. The fluorescent proteins mCherry and YFP are a FRET pair and thus report on the separation between the C-termini of the TM domains in a FGFR1 dimer (25). Measurements were performed in plasma membrane derived vesicles, as previously described (62). High concentration of ligand (250 nM) was used, to ensure that all receptors are ligand-bound. We followed a quantitative protocol (termed QI-FRET) which yields (i) the FRET efficiency, (ii) the donor concentration, and (iii) the acceptor concentration in each vesicle (63). A few hundred vesicles, imaged in multiple independent experiments, were analyzed and the data were combined.

Figure 6A, left, shows the FRET efficiencies as a function of total FGFR1 concentration in the presence of the three ligands, where each data point corresponds to one individual vesicle derived from one cell. The total FGFR1 concentration, on the x axis in **Figure 6A**, left, is the sum of ECTM FGFR1-YFP and ECTM FGFR1-mCherry concentrations. In **Figure 6A**, right, we further show the expressions of ECTM FGFR1-YFP and ECTM FGFR1-mCherry in the individual vesicles. Because transient expression levels vary from cell to cell, the vesicles produced in a single transfection experiment had a wide range of receptor concentrations.

We see that FRET in **Figure 6A** does not depend on the concentration, over a broad receptor expression range, indicative of constitutive FGFR1 association in the presence of the FGF4, FGF8, and FGF9. To interpret the FRET data, we need to know the oligomer size of the ECTM FGFR1 construct. FIF experiments (not shown) demonstrated that the ECTM construct always forms dimers, even in the presence of high FGF4 concentration. Thus, the data in **Figure 6** correspond to ligand-bound ECTM FGFR1 dimers; in this case FRET depends only on (i) the fraction of acceptor-labeled FGFR1, which is directly calculated from the data in **Figure 6A** and (ii) the so-called Intrinsic FRET, a structural parameter which depends on the positioning and dynamics of




Figure 6

Structural basis of FGFR1 ligand bias. (A) and (B). FRET Data for ECTM-FGFR1-YFP and ECTM-FGFR1-mCherry in the presence of saturating FGF4 (orange), FGF8 (green) or FGF9 (blue) concentrations. (A) Measured FRET efficiencies versus total receptor (ECTM-FGFR1-YFP + ECTM-FGFR1-mCherry) concentrations and measured donor (ECTM-FGFR1-YFP) concentrations versus acceptor (ECTM-FGFR1-mCherry) concentrations in single vesicles. (B) Histograms of single-vesicle intrinsic FRET values. Intrinsic FRET is a measure of the separation between the fluorescent proteins in the dimer. Different intrinsic FRET values were measured for FGF8 and FGF4/FGF9. (C) Graphical representation of experimental results showing that FGF8 induces a TM dimer conformation where the TM C-termini are positioned further apart from each other, as compared to the cases of FGF4 and FGF9. Also shown is a hypothesis that each TM domain dimer conformation defines an ensemble of kinase dimer conformations that ensures the preferential phosphorylation of one tyrosine over another. (D) FGFR1 kinase dimer structures generated by ClusPro from PDB 3GQI were optimized by creating 2,000 decoys with PyRosetta. The interface scores for the decoys are plotted as a function of RMSD. The results for four lowest energy sets of decoys are shown, represented with different colors. (E) Models of the four lowest-energy FGFR1 kinase domain dimer structures.

the two fluorophores (64). An Intrinsic FRET value was calculated for each vesicle from the data in **Figure 6A** using **equation 5**. The values were binned to generate a histogram and are shown in **Figure 6B**. These histograms were fitted with Gaussians, yielding Intrinsic FRET values of 0.54 ± 0.01 , 0.42 ± 0.01 and 0.52 ± 0.01 , for the cases of FGF4, FGF8, and FGF9, respectively. Thus, intrinsic FRET is lower for FGF8-bound ECTM FGFR1 dimers, as compared to FGF4 and FGF9-bound ECTM FGFR1 dimers. Since the fluorescent proteins were attached directly to the TM domains via flexible linkers, the measured differences in Intrinsic FRET reflect differences in the separation of the C-termini of the TM domains in the presence of FGF8, compared to FGF4 and FGF9. Thus, the TM domain dimer structure is different in the FGF8-bound FGFR1 dimers as compared to FGF4 and FGF9-bound dimers.

The effective distances between the fluorescent proteins in the ECTM FGFR1 dimers are calculated using **equation 6**, assuming random orientation of the fluorophores (justified because they were attached via flexible linkers). In the presence of FGF4 and FGF9, the effective distance between the fluorescent proteins is the same, $55 \pm 1 \text{ \AA}$ and $56 \pm 1 \text{ \AA}$ ($p > 0.05$). In the presence of FGF8, the effective distance between the fluorescent proteins is significantly higher, $60 \pm 1 \text{ \AA}$ ($p < 0.01$) as shown in **Figure 6C**. These structural differences may underlie the observed signaling bias in response to FGF8, as compared to FGF4 and FGF9.

FGFR kinase conformations and a hypothesis about the mechanism of signaling bias

To gain insight into the interactions between the two kinases in the FGFR1 dimer, we used the active monomeric kinase domain (PDB 3GQI) and generated *in silico* predictions of the dimer structure using ClusPro 2.0 (65, 66) and PyRosetta (67). First, ClusPro was used to create 10 low energy dimers. In PyRosetta, each of the 10 dimer structures was subjected to 2,000 independent randomized perturbations resulting in a total of 20,000 unique dimer structures. Each dimer interface was scored using a Rosetta scoring function and plotted against the RMSD of the structure relative to the initial structure “0” from ClusPro.

In **Figure 6D** we show the interface scores as a function of the RMSD values to visualize an “energy funnel” for each set of decoys originating from the same ClusPro structure. A ClusPro structure is considered more stable than others if it exhibits a lower interface score (indicating a lower energy interface) than the other structures and if it converges to a single RMSD value. In **Figure 6F**, we show four kinase dimer structures that correspond to the most stable configurations identified in Rosetta. Tyrosines 653/654 in the activation loop are shown in yellow in these structures. Structure 1, shown in pink, represents the most stable structure and has tyrosine 766 of one kinase positioned in the active site of the second kinase. This could represent the structure responsible for phosphorylation of Y766. Importantly, this most stable kinase dimer structure cannot be the only structure that is explored, as it is known that multiple tyrosines, in addition to Y766, are phosphorylated in the FGFR1 dimer. In structure 2, shown in orange, the active site of one of the kinases faces the same direction as the N-lobe of the other kinase. It is thus likely that this active site is oriented towards the juxtamembrane domain and the membrane. This could be a kinase dimer structure that allows the phosphorylation of FRS2, which is known to bind to the juxtamembrane domain. Structure 3, shown in purple, has the C-lobe of both kinases in contact with each other. Here the active site of one kinase is solvent exposed, and so is tyrosine 766 on the other kinase. This is a kinase dimer conformation that could allow the phosphorylation of PLC γ after recruitment by tyrosine 766. In structure 4, shown in red, the active sites of the two kinases are facing away from each other, towards the solvent. This could represent a structure that allows the phosphorylation of downstream substrates.

We propose that all these structures are explored in the signaling competent FGFR1 dimer, because multiple tyrosines have to be phosphorylated. Note that the simulations were performed for the isolated kinase domains. This is a simplified system which likely omits significant

components influencing the interaction, i.e. the TM domain and the juxtamembrane domain, a linker sequence connecting the kinase domain with the TM domain. It is conceivable that structural constraints imposed by the TM domains affects the stabilities of the kinase-kinase interfaces, and thus the relative frequencies with which the different kinase dimer conformations are explored in the FGFR1 dimer. It is possible that these structures are differentially explored within the FGF8 and FGF9-bound FGFR1 dimers (a hypothesis is illustrated in **Figure 6C**). A kinase dimer conformation, corresponding to either Y766 phosphorylation or FRS2 phosphorylation, is shown as a solid colored cartoon when it is the preferred conformation. The translucent cartoons represent a conformation that is less energetically favorable, but is nevertheless explored. Note that both FGF8 and FGF9-bound FGFR1 dimers explore the same kinase dimer conformations, but the preferences change depending on the TM domain conformation. The cartoon further illustrates the finding that in the FGF8-stabilized FGFR1 dimer conformation the C termini of the TM domains are farther apart, as compared to the FGF9-stabilized FGFR1 dimer.

Finally, we sought to create models of FGFR1 kinase domain trimers by aligning a kinase domain from one dimer with a kinase domain from a second dimer. In some cases, this led to steric clashes, suggesting that these trimers are unlikely to form. Trimer structures without steric clashes are shown in Figure S2, and they demonstrate the feasibility of kinase oligomerization. It is thus possible that multiple kinase interfaces can be engaged to stabilize the FGFR1 oligomers observed in the FIF study in **Figure 2**. Furthermore, the activity of the kinases in the dimers and the oligomers may be different. As argued above, lower activity in the oligomers could explain why FGFR1 oligomerization at high FGF4 concentration leads to reduced phosphorylation.

Discussion

The most significant discovery in this work is the existence of bias in FGFR1 signaling in response to tree FGF ligands that FGFR1 naturally encounters during limb development. This concept of “ligand bias” is a relatively novel in RTK research (68). It describes the ability of ligands to differentially activate signaling pathways (46, 47, 69). Ligand bias has been studied primarily in the context of G-protein coupled receptors (GPCRs) and has transformed the fundamental understanding of GPCR signaling (47). Importantly, these investigations have produced optimized protocols to identify and quantify bias that are directly applicable to RTKs (68). Here we use such quantitative protocols to demonstrate that FGF8 but not FGF4 or FGF9 preferentially induces FRS2 phosphorylation, when compared to the phosphorylation of FGFR1 tyrosines. We also demonstrated that FGF8 preferentially induces collagen 2 loss over growth arrest, as compared to FGF4 and FGF9.

It must be noted that the term „RTK ligand bias“ is often used in the literature to indicate any difference in signaling due to ligands. Here we use this term according to its classical definition, namely the differential activation of at least *two* different signaling responses (46, 47, 69). The term „bias“ is distinctly different from the potencies and efficacies of a ligand for one particular response. For example, in **Figure 5E** we see that FGF8 has both lower potency and lower efficacy than FGF4, but these data cannot provide any information about bias. Bias can be assessed only if the data in **Figure 5E** are compared to the data in 5F, leading us to conclude that FGF8 is biased towards collagen 2 loss and against growth arrest, as compared to FGF4, despite the fact that FGF8 has the lowest potency and the lowest efficacy in inducing collagen loss. Potency, efficacy, and bias describe distinct aspects of RTK signaling, yet the differences in these characteristics have not been explicitly considered in prior studies of FGF signaling.

Ligand bias studies requires the comparison of at least two responses and at least two ligands (46, 47, 69). Prior studies of the effects of different FGFs on FGFR signaling have utilized BAF/3 cells (9–11). In these cells, only a single response, cell proliferation, can be quantified

and compared, and thus these cells cannot be used for bias studies. In HEK293T cells, the functional effects due to the FGF4, FGF8, and FGF9 are modest (**Figure 5A-C**). However, we were able to measure dose response curves for two functional responses in engineered RCS^{fgfr1} cells (**Figure 5E**, F). These cells allow to model processes occurring in the developing mammalian limb, where the three FGF ligands (FGF4, FGF8, FGF9) released by the ectoderm at the surface of the limb bud signal to the underlying mesenchymal cell expressing just one FGF receptor, FGFR1c (17, 18).

In RCS cells, cellular phenotypes caused by FGF signaling can be quantified, and thus RCS cells have been used in studies exploring the mechanisms of FGF-FGFR signaling, including mechanisms behind FGF regulation of the cell cycle, cell proliferation, differentiation, premature senescence, loss of extracellular matrix, interplay between FGF and WNT signaling, cytokine and natriuretic peptide signaling, and others (56, 57, 70–75). In addition, treatments inhibiting pathological FGFR signaling, which are now either in human trials (RBM007, meclozine) or are FDA-approved (vosoritide), were initially developed in RCS cells, benefiting from the well characterized molecular mechanisms of FGF signaling in these cells (21, 76, 77). Here we show that RCS cells can also be used to identify biased FGF ligands.

Having established the existence of bias in FGFR1 signaling, we sought the mechanism that allows for the recognition of FGF8 binding to FGFR1 EC domain, as compared to FGF4 and FGF9. We measured FRET occurring in truncated FGFR1 dimers with fluorescent proteins attached to the C-termini of the TM helices via flexible linkers. We showed that FRET is different when FGF8 is bound to the EC domain, as compared to the cases of bound FGF4 and FGF9. These results suggest that the C-termini of the TM helices are spaced further apart in the FGF8-bound FGFR1 dimers as compared to FGF4 and FGF9-bound dimers. Thus, FGFR1 TM domains must sense the identity of the ligand that is bound to the EC domain. FRS2 binds to the JM domain, which immediately follows the TM domain (42, 60, 78). It is easy to envision that the conformation of the TM domain affects FRS2 behavior, as the FRS2 binding site is just 32 amino acids from the TM domain C-terminus. The larger TM domain separation in the FGF8-bound FGFR1 dimers may facilitate the preferential phosphorylation of FRS2 over other sites. Alternatively, the smaller TM domain separation upon binding of FGF4 and FGF9 may disfavor FRS2 phosphorylation. Further, the differential phosphorylation of FRS2 may be due to a different mode of FRS2 binding to FGFR1, differences in the accessibility of FRS2 by the active site of the FGFR1 kinase, or different accessibility of FRS2 by phosphatases.

A question arises as to whether the structural differences in the TM domain dimers can impact the kinase domain dimer conformations. This is a challenging question to answer, as the very mechanism of RTK signal propagation from the EC domains to the kinase domains is currently unknown. To a large extent, this is due to a complete lack of high-resolution structures of full-length RTKs. Furthermore, electron microscopy studies have unequivocally shown that there is no simple one-to-one correspondence between distinct EC and IC domain conformations (79, 80). This has led us to propose that every ligand-bound RTK dimer explores an ensemble of microstates, each characterized by different kinase domain dimer structures (81). The typical role of a microstate is to ensure the phosphorylation of one specific tyrosine. Additional microstates may serve as intermediates in the transitions between two phosphorylation-competent configurations, or may serve to recruit effector proteins by exposing phosphorylated tyrosines. The prevalence of a certain microstate (or its residence time, or its weight within the microstate ensemble) has been proposed to correlate with its stability, i.e., with the favorable contacts between the two chains in the full-length dimer (81). The fact that many different kinase domain conformations are experimentally observed (as multiple tyrosines are phosphorylated) suggests that multiple microstates have similar stabilities, and thus similar residency times. This view is consistent with our Rosetta calculations, where we see multiple kinase dimer conformations that may be allowing for the phosphorylation of different tyrosines in the kinase domain, as well as tyrosines in effector molecules such as FRS2.

It can be envisioned that constraints imposed by the TM domains on the kinase domains may be sufficient to alter the relative stabilities of the different kinase dimer configurations in response to different ligands. Thus, the TM domain conformation may determine which cytoplasmic tyrosines are most efficiently phosphorylated, leading to the differential activation of downstream effectors (82 [↗](#)). We can therefore explain FGFR1 ligand bias using structural arguments, by postulating that the FGF9-bound FGFR1 dimer state, which is characterized by a smaller separation between the TM domain C-termini, defines an ensemble of kinase dimer conformations that ensures the preferential phosphorylation of Y766 phosphorylation over FRS2 phosphorylation. On the other hand, a larger TM domain separation in the FGF8-bound FGFR1 dimer allows the preferential phosphorylation of FRS2 over Y766.

It is important to note that there are researchers who disagree that structural information can be propagated along the length of the RTK, because the linkers between the RTK domains are flexible (50 [↗](#), 83 [↗](#), 84 [↗](#)). If so, how do the kinases sense which ligand is bound to the EC domain? Some have proposed that differential downstream signaling occurs as a result of different kinetics of receptor phosphorylation/de-phosphorylation in response to different ligands (50 [↗](#)). There is a report that tyrosine phosphorylation of EGFR is more sustained in response to epigen and epiregulin than to EGF (50 [↗](#)). Specifically, it was found that EGF-induced EGFR phosphorylation of Y845, Y1086, and Y1173 returned to baseline much faster, as compared to phosphorylation in response to epigen and epiregulin (50 [↗](#)). The authors argued that differences in kinetics do not depend on the specific ligand concentration used, and they attributed the characteristic kinetics of the response to the identity of the bound ligand. In other studies with other RTKs, however, the concentration of the ligand strongly influenced the kinetics of the response, questioning the applicability of this model to all RTKs (85 [↗](#), 86 [↗](#)). Here we show that FGFR1 kinetics of phosphorylation also depend strongly on FGF concentration. Furthermore, we do not observe a discernable correlation between kinetics of FGFR1 phosphorylation and ligand bias, which provides further support for the importance of the FGFR1 dimer structure as a determinant of FGFR1 ligand bias.

We further see marked differences in the potencies of the three FGFs. Indeed, 50% of maximum phosphorylation in 293T cells is reached for ~0.5 nM FGF4, ~2 nM FGF9, and ~10 nM FGF8. Thus, the same level of phosphorylation of a specific tyrosine can be achieved for much lower concentrations of FGF4, as compared to FGF8 or FGF9. The potencies of FGF4 in inducing functional responses are also the highest in RCS cells. These potencies are expected to correlate with the binding affinities of the ligands for FGFR1. The reported dissociation constants, measured for FGF4/FGFR1 and FGF9/FGFR1 using surface plasmon resonance in the context of the isolated and truncated FGFR1 EC domains are 170 nM and 1200 nM, respectively (87 [↗](#)). Thus, FGF4 binds FGFR1 about an order of magnitude tighter than FGF9, consistent with the difference in potencies that we measure here.

We also observe differences in the efficacies of the three FGF ligands. The highest phosphorylation in **Figure 3** [↗](#) is achieved in response to high concentrations of FGF8. FGF8 is a full agonist while FGF4 and FGF9 are partial agonists for most of the responses (with the exception of FRS2 phosphorylation). Along with differences in potencies and efficacies, we observe a significant difference in the very shape of the dose response curves. In particular, the FGF4 dose response does not follow the anticipated rectangular hyperbolic shape, unlike the cases of FGF8 and FGF9. We see that the FGF4-induced phosphorylation of FGFR1 and the effector molecules increases up to ~3 nM FGF4, and then gradually decreases as FGF4 concentration is further increased. The mechanism behind the decrease in activation at high FGF4 concentration is unknown, but our data suggest that it cannot be explained with differential kinetics of de-phosphorylation/downregulation. Furthermore, there is no correlation between the unusual shape of the FGF4 dose response and ligand bias, as FGF4 is not biased when compared to FGF9. Instead, we see an intriguing correlation between the decrease in FGFR1 phosphorylation and the appearance of FGFR1 oligomers that are larger than dimers. Indeed, the FIF data in **Figure 2** [↗](#)

suggests that high FGF4 concentration promotes oligomerization of FGFR1. Oligomers are observed in full-length FGFR when bound to FGF4, but not when the kinase domains are deleted. This finding suggests that, at least in part, the oligomers are stabilized by kinase-kinase contacts. In support of this view, our simulations reveal that FGFR1 kinase oligomers can form from the kinase dimers identified in PyRosetta, without steric clashes (Figure S2).

We can explain the shape of the FGF4 dose response curves if we assume that phosphorylation is less efficient in FGFR1 oligomers as compared to FGFR1 dimers. It is important to note that another RTK, EGFR, has also been proposed to form oligomers in response to EGF, in addition to dimers (88 [↗](#), 89 [↗](#)). EGFR dimers and oligomers have been proposed to have different activities (88 [↗](#), 89 [↗](#)). It has been suggested that in the EGFR oligomer, each EGFR kinase may be able to phosphorylate and be phosphorylated by multiple neighboring kinases, leading to higher overall activation. Such a view, however, is not consistent with the FGFR1 data presented here. Perhaps, the functional role of FGFR1 oligomers is very different from that of the EGFR oligomers, as oligomerization seems to inhibit FGFR1 signaling.

Biochemical signals, once propagated across the plasma membrane, are known to be amplified in the cytosol. Modest, but statistically significant differences are observed in the function of 293T cells. We find that FGF8 is more efficient than FGF9 at promoting FGFR1 removal from the plasma membrane and cellular apoptosis in 293T cells. However, large differences in ERK activation and in functional responses due to the three ligands were observed in RCS^{Fgfr1} cells, which mimic the proliferating chondrocytes involved in limb development and growth. We also observed much higher potencies of the FGF ligands in RCS cells than in 293T cells. These observations are consistent with the idea that modest differences in signal propagation across the plasma membrane that are due to the identity of the bound ligand can become significant due to signal amplification which is cell-specific. They underscore the importance of biophysical studies of RTK activation in the plasma membrane for understanding cellular functions.

In conclusion, we initiated this study in search of a possible difference in the response of FGFR1 to three FGF ligands. We found not one, but many differences. We observed quantitative differences in most aspects of the FGFR1 signaling response: ligand-induced oligomerization, potency, efficacy, and conformations of FGFR1 TM domain dimer. We also discovered the existence of ligand bias in FGFR1 signaling. The quantitative tools that we used were instrumental in revealing these differences, based on the analysis of FGFR1 dose response curves for the three ligands. Of note, such dose response curves are typically collected for GPCRs (48 [↗](#), 90 [↗](#)–92 [↗](#)), but rarely for RTKs. Future use of such quantitative tools for other RTKs may similarly reveal unexpected differences in response to different ligands and may uncover exciting new biology.

All 58 RTKs have been implicated in many growth disorders and cancers (1 [↗](#), 93 [↗](#)–95 [↗](#)), and have been recognized as important drug targets. Inhibitors that specifically target the RTKs have been under development for decades now. Recent years have seen significant improvements in RTK-targeted molecular therapies, but these therapies have not yet fundamentally altered the survival and the quality of life of patients (96 [↗](#), 97 [↗](#)). This may be because RTK signaling is much more complex than currently appreciated, as demonstrated here for FGFR1. Furthermore, it is possible that ligand bias plays an important role in RTK-linked pathologies. The practice of evaluating bias for novel RTK-targeting therapeutics will empower the discovery of a new generation of biased RTK inhibitors that selectively target pathogenic signaling pathways, and thus exhibit high specificity and low toxicity.

Cell Culture

Human embryonic kidney cells (HEK293T), stably transfected with FGFR1-YFP, and RCS cells were grown in Dulbecco's modified eagle medium (DMEM; Thermofisher, PN 31600034) with 10% fetal bovine serum and supplemented with 3.5 grams of glucose and 1.5 grams of sodium bicarbonate. The Chinese Hamster Ovarian (CHO) cells were grown in DMEM with 10% fetal bovine serum and supplemented with 0.8 grams of glucose and 1.5 grams of sodium bicarbonate and 1% NEAA at 37°C and 5% CO₂. The RCS *Fgfr1-4 null* cells were prepared by Crispr/Cas9-mediated inactivation of *Fgfr1*, *Fgfr2*, *Fgfr3*, and *Fgfr4* loci (21 [DOI](#)). RCS^{Fgfr1} cells were prepared in similar manner, only this time the *Fgfr1* locus was not targeted.

Western blots

HEK 293T cells stably expressing FGFR1 were seeded in equal volumes into 12 well plates and allowed to grow to ~70-90% confluency, while changing the media after 48 hours. The full media was aspirated and replaced with Dulbecco's modified eagle medium without FBS. Varying amounts of ligands (R&D systems; FGF4, #235-F4-025; FGF8, #423-F8-025, and FGF9, # 273-F9-025) were added to each well to create a ligand concentration gradient. Cells were incubated with the ligands at 37°C and 5% CO₂ for 20 minutes and then immediately placed on ice. Media was aspirated and cells were immediately lysed with 2x Laemmli Buffer (BioRad 1610737) + 5% BME. Lysates were moved to clean Eppendorf tubes and vortexed for 10 second intervals 6 times over the course of 5-10 minutes, staying on ice in the interim. Lysates were centrifuged, boiled at 98°C for 10 min, and then immediately placed on ice until cool. Lysates were then centrifuged again and stored at -20°C for later use. Lysates were thawed on ice and vortexed immediately prior to loading onto gel. Gels were run on ice at 140V for 3 hours using Bio-Rad Mini-Protean TGX precast gels in 1X Tris/Gly/SDS running buffer (BioRad #1610732). Gels were then equilibrated with transfer buffer (BioRad #1610734) supplemented with 20% methanol for 10 min. Western transfer was performed using the Iblot 2 Gel Transfer Device (Thermofisher #IB21001) and nitrocellulose packs (Thermofisher IB23001). Nitrocellulose membranes were removed and replaced with PVDF membranes (BioRad #1620177) that had been activated in 100% methanol, all other steps were as prescribed by Thermofisher. Transfers were done at 25V for 7 minutes. Following transfer, membranes were immediately trimmed and placed in either 5% non-fat milk or 5% BSA in 1X TBS supplemented with 1% Tween (Thermofisher #1706475) (TBST) depending on the primary antibody used. Blocking was accomplished on a rocker for 1-2 hours at room temperature. Membranes were rinsed 2X with TBST and then primary antibody was added at a 1:1000 dilution. Primary antibodies (Cell Signaling: anti-Y653/654 #3471S, anti-FGFR1 #9740S, anti-pY766 FGFR1, #2544, anti-Actin #3700, anti-pERK1/2 #9101, anti-pFRS2 #3861S, anti-pPLCy #2822, anti-PLCy #2821, anti-Vinculin #13901; SantaCruz: anti-FGFR2 #sc122; Cedarlane: anti-collagen 2 #CL50241AP; Invitrogene: anti-V5 #46-0705) were incubated with the membrane overnight at 4°C on a rocker. The primary antibody was removed and the membrane was washed with TBST 3 times for 5-15 min. The secondary antibody (Promega: anti-rabbit #W4011; Sigma: anti-mouse #A6782) was added at a dilution of 1:10000 and allowed to incubate on a rocker at room temperature for 1-2 hours. The secondary antibody was removed and the membrane was washed with TBST 3x for 5-15 min. The membrane was incubated with chemiluminescent solution (Thermofisher Scientific West Femto Supersignal, #1706435) and imaged on a Bio-Rad Gel-Doc XRS+.

Blot images were stored digitally. The intensity of each band was quantified using imageJ. Intensities were scaled following a protocol in Supplemental Information.

Phosphorylation dose response curves

The band intensities from at least 3 and up to 5 independent samples were quantified. The intensities were averaged and plotted as a function of ligand concentration for each response. The averaged dose response curves for the three ligands were scaled to each other. This was accomplished by re-running the samples that yielded the highest phosphorylation band intensities for a specific response on the same blot (**Figure 3B**). Intensities for each ligand on the common blot were averaged and the averages for the different ligands were scaled by setting the maximum value to 1. The scaled dose response curves were fitted to a rectangular hyperbolic (Hill equation with $n=1$) given by:

$$response = \frac{[x] * E_{top}}{[x] + EC_{50}} \quad \text{eqn 1}$$

Here $[x]$ represents the concentration of ligand, while E_{top} corresponds to the plateau at high ligand concentrations and EC_{50} corresponds to the ligand concentration value at which 50% of E_{top} is achieved.

To fit the data to **eqn 1**, we truncated each dose response curve at the highest ligand concentration that is within 10% of the maximum y value. This took into account that the average y value error is between 5-10%. The data was fit in Mathematica with the Nonlinear Model fit function using the Levenberg-Marquardt minimization method, while allowing for a maximum of 100,000 iterations. The errors of the fit were weighted as the inverse of the square of the error.

Calculation of bias coefficients

To calculate bias coefficients, FGF8 was chosen as the reference ligand. Bias coefficients, β , for FGF4 and FGF9 were calculated using **eqn 2**.

$$\beta_{4,9} = \text{Log} \left(\left(\frac{E_{top,1}}{EC_{50,1}} * \frac{EC_{50,2}}{E_{top,2}} \right)_{4,9} * \left(\frac{EC_{50,1}}{E_{top,1}} * \frac{E_{top,2}}{EC_{50,2}} \right)_8 \right) \quad \text{eqn 2}$$

Standard errors of β are calculated using the standard errors of EC_{50} and E_{top} , as determined from the fit in **eqn 1**, using the functional approach for multi-variable functions (98).

To compare bias coefficients for the three ligands and determine statistical significance in a three-way comparison, we follow the protocol in (68), re-writing **eqn 2** as:

$$\beta_{4,9} = \beta'_{4,9} - \beta'_8 \quad \text{eqn 3}$$

Where β' is calculated in **equation 4**.

$$\beta'_{4,8,9} = \text{Log} \left(\frac{E_{top,1}}{EC_{50,1}} * \frac{EC_{50,2}}{E_{top,2}} \right)_{4,8,9} \quad \text{eqn 4}$$

Standard errors of β' were calculated using the standard errors of EC_{50} and E_{top} using the functional approach for multi-variable functions (98). The β' values and their corresponding errors are reported in Table S1.

Statistical significance of the differences between β' values were calculated with a one-way ANOVA using the multi-variable analysis option in Prism. The data that were inputted were the mean, SEM, and n, the number of points contributing to the fit. $n=9$ for FGF4, $n=10$ for FGF8 and $n=7$ for FGF9. The calculated p-values are shown in Table S2.

FRET measurements

CHO cells were seeded into tissue culture-treated 6-well plates at a density of 2×10^4 cells/well. 24 hours later, the cells were co-transfected with FGFR1-ECTM-eYFP and FGFR1-ECTM-mCherry using Eugene HD (Promega # E2311) according to the manufacturer's instructions. ECTM constructs included the entire extracellular domain and transmembrane domain up to residue 402, followed by a (GGG)₅ flexible linker and the fluorophore (25). The amount of DNA as well as the donor to acceptor ratio of the DNA added was varied to achieve a wide range of donor and acceptor expressions (62).

Cells were vesiculated ~24 hours after transfection as described previously (99). Briefly, the cells were rinsed 2x with 30% PBS and then incubated for 13 hours at 37°C and 5% CO₂ in a chloride salt buffer. Vesicles were then transferred to 4-well glass-bottomed chamber slides for imaging on a Nikon confocal microscope with a 60x objective to capture images of the equatorial cross-sections of the vesicles in 3 channels: donor (eYFP), acceptor (mCherry), and FRET (58). FRET was measured following the QI-FRET protocol (62, 64), which yields the donor concentration, the acceptor concentration, and the FRET efficiency in each vesicle. The microscope was calibrated using solutions of fluorescent protein of known concentration, so that the fluorescence intensity could be directly correlated to fluorophore concentration.

In the case of constitutive dimers at high ligand concentration, when FRET does not depend on receptor concentration,

$$\tilde{E} = \frac{E}{x_A} \quad \text{eqn 5}$$

the measured FRET and the Intrinsic FRET are connected as follows (63): Here x_A is the acceptor fraction, which is measured in each vesicle, along with the FRET efficiency, E . Equation 5 allows us to directly determine the value of the intrinsic FRET, $\tilde{E}$, in each vesicle. The dependence of the intrinsic FRET, $\tilde{E}$, on the distance between the fluorescent proteins in the dimer, d , is given by equation (6).

$$\tilde{E} = \frac{1}{1 + \left(\frac{d}{R_0}\right)^6} \quad \text{eqn 6}$$

Here R_0 is the Förster radius of the FRET pair. For eYFP and mCherry, R_0 is 53.1 Å (64, 100). This equation assumes free rotation of the fluorescent proteins. This assumption can be justified because the fluorescent proteins are attached via flexible linkers.

Fluorescence Intensity Fluctuations (FIF) spectrometry

HEK 293T cells, stably transfected with FGFR1-YFP, were seeded on collagen-coated, glass bottom petri dishes (MatTek, P35GCOL-1.5-14-C) and allowed to grow to ~70% confluency at 37°C and 5% CO₂. Cells were grown in Dulbecco's modified eagle medium with 10% fetal bovine serum, supplemented with 3.5 grams of glucose and 1.5 grams of sodium bicarbonate. Cells were rinsed with 70% swelling media (1:9 serum-free media, diH₂O, 25 mM HEPES), and then swelled in 70% swelling media plus ligand for ~5 min before imaging. This treatment minimizes the ruffles in the plasma membrane and prevents endocytosis (101, 102).

The plasma membranes facing the support were imaged on a TCS SP8 confocal microscope using a photon counting detector. Images were analyzed using the FIF software (26). Briefly, the membrane was divided into 15 x 15 pixel regions of interest and the molecular brightness, ϵ of each region was calculated as:

$$\epsilon = \frac{\sigma^2}{\langle I \rangle} - 1 \quad \text{eqn 7}$$

where θ is the center of the Gaussian distribution and σ^2 is the variance in each segment. The brightness values from thousands of regions of interest were binned and histogrammed. The histograms were then normalized to 1.

Since the molecular brightness distribution is log-normal, the values of $\log(\text{brightness})$ were histogrammed and fit to a Gaussian function:

$$\text{normalized counts} = a * e^{\frac{-(\theta-m)^2}{2*s^2}} \quad \text{eqn 8}$$

Here θ represents the log of the brightness, m is the mean of the Gaussian, s is the standard deviation of the Gaussian, and a is a constant. The best fit Gaussian parameters are shown in Table S3.

In order to determine whether the distributions were the same or different, a Z-statistics analysis was used, where the Z value is given by:

$$Z = \frac{m_1 - m_2}{\sqrt{q_1^2 + q_2^2}} \quad \text{eqn 9}$$

Here m_1 and m_2 represent the two means of the Gaussians being compared, and q_1 and q_2 are the standard deviations for each Gaussian divided by the square root of the number of cells analyzed. A minimum of 100 cells were analyzed for each data set.

A Z value of less than 2 means that the data sets are within 2 standard deviations of the mean and are therefore the same, while a Z value greater than 2 means that the two data sets are different (37). Calculated Z values can be found in Table S3.

Ligand-induced FGFR1 removal from the plasma membrane

FGFR1 downregulation in the plasma membrane was assayed by measuring the FGFR1 membrane concentration before and 2 minutes after ligand addition. FGFR1-YFP in the plasma membrane in contact with the substrate was imaged in a TCS SP8 confocal microscope, and FGFR1-YFP fluorescence per unit membrane area was quantified. HEK 293T cells, stably transfected with FGFR1-YFP, were seeded on collagen-coated, glass bottom petri dishes (MatTek, P35GCOL-1.5-14-C) and allowed to grow to ~70% confluency at 37°C and 5% CO₂. Cells were rinsed with serum-free media and exposed to 130 nM of either FGF8 or FGF9 or no ligand and incubated at 37°C and 5% CO₂ for 2 minutes. The cells were fixed in a solution of 4% formaldehyde in PBS for 20 min at room temperature. Samples were stored at 4°C prior to imaging. A minimum of 100 cells per condition were imaged, in three independent experiments. The receptor concentration in the membrane of each cell was quantified using the FIF software (26), and results for all analyzed cells per condition were averaged.

Apoptosis Assays

Apoptosis was probed using the Bio-Rad Magic Red Caspase 3-7 kit (Bio-Rad, ICT 935). HEK 293T cells stably expressing FGFR1-YFP were seeded in 96 well plates and allowed to grow to ~70% confluency. Media was aspirated and replaced with serum-free media with the Magic Red staining solution and varying concentrations of ligand. After ligand treatment the cells were placed in the incubator at 37°C and 5% CO₂ for 6 days. The fluorescence of the cleaved substrate (Cresyl Violet) was measured on a Synergy H4 plate reader. The excitation wavelength was 592 nm. Emission was measured at 628 nm.

Viability Assays

Cell viability was monitored using a MTT Cell Proliferation Assay Kit (Cell BioLabs, #CBS-252). HEK 293T cells, stably transfected with FGFR1-YFP, were seeded in 96 well plates and allowed to grow to ~70% confluency. Media was aspirated and replaced with serum-free media and with varying concentrations of ligand. After ligand addition, cells were kept at 37°C and 5% CO₂ for 6 days. Viability was measured according to the manufacturer's protocol. Briefly, CytoSelect MTT Cell Proliferation Assay Reagent was added directly to the cell media. After three hours of incubation at 37°C and 5% CO₂, the cells were lysed with detergent and kept at room temperature for 2 hours. The absorbance was measured on a Synergy H4 plate reader at 555 nm.

ERK activation, cell count and collagen

expression experiments in RCS^{Fgfr1} cells

The pKrox(MapERK)d1EGFP reporter was stably expressed in RCS^{Fgfr1} cells using the piggyBac transposase. Activation of the pKrox(MapERK)d1EGFP reporter in RCS^{Fgfr1} cells was measured using an automated incubation microscope BioStation CT (Nikon, Tokio, Japan). Phase contrast and fluorescence signal images were automatically acquired every 1 hour during a 48 hr time period. Fluorescence of the reporter was then processed and analyzed in Nikon BioStation CT software. For growth-arrest assay, the RCS cells were treated with 1 µg/ml heparin and fgf ligands for three days. Cell numbers were determined by counting (Beckman-Coulter). For collagen type 2 expression, the RCS cells were treated with 1 µg/ml heparin and FGF ligands for 48 hours and collagen type 2 expression was measured by western blotting.

Interface predictions with ClusPro and PyRosetta

The monomeric kinase domain structures were docked using the ClusPro 2.0 software ([65](#), [66](#)). The top ten dimer structures were selected based on ClusPro 'VdW+Elec' (Van der Waals and electrostatic) energy calculations. Each dimer interface was further optimized by introducing randomized structural perturbations to generate two thousand structural decoys using a custom-written code that employs the PyRosetta modeling suite ([67](#)). The resulting 20,000 dimer structures generated were scored using PyRosetta interface scoring functions ([103](#)). The RMSDs were calculated relative to a pre-optimized ClusPro structure. The dimer structures with the lowest interface score for each set of decoys were selected as the optimized dimer structures.

Acknowledgements

We thank Marie Tesarova for excellent technical assistance. Supported by NIH GM068619 and NSF MCB 2106031. PK is supported by the Czech Science Foundation (GA19-20123S, GF21-26400K); Ministry of Education, Youth and Sports of the Czech Republic (INTER-ACTION LUAUS23295); Grant Agency of Masaryk University (MUNI/G/1771/2020); National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) - Funded by the European Union - Next Generation EU. BF is supported by the Agency for Healthcare Research of the Czech Republic (NU21-06-00512).

References

1. Lemmon M. A., Schlessinger J. (2010) **Cell Signaling by Receptor Tyrosine Kinases** *Cell* **141**:1117–1134
2. Schlessinger J (2000) **Cell signaling by receptor tyrosine kinases** *Cell* **103**:211–225
3. Paul M. D., Hristova K. (2019) **The RTK Interactome: Overview and Perspective on RTK Heterointeractions** *Chem Rev* **119**:5881–5921
4. Goetz R., Mohammadi M. (2013) **Exploring mechanisms of FGF signalling through the lens of structural biology** *Nat.Rev.Mol.Cell Biol* **14**:166–180
5. Eswarakumar V. P., Lax I., Schlessinger J. (2005) **Cellular signaling by fibroblast growth factor receptors** *Cytokine Growth Factor Rev* **16**:139–149
6. Schlessinger J (2004) **Common and distinct elements in cellular signaling via EGF and FGF receptors** *Science* **306**:1506–1507
7. Tomlinson D. C., Lamont F. R., Shnyder S. D., Knowles M. A. (2009) **Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer** *Cancer Res* **69**:4613–4620
8. Ornitz D. M., Itoh N. (2001) **Fibroblast growth factors** *Genome Biology* **2**
9. Ornitz D. M., Xu J. S., Colvin J. S., McEwen D. G., MacArthur C. A., Coulier F., Gao G. X., Goldfarb M. (1996) **Receptor specificity of the fibroblast growth factor family** *Journal of Biological Chemistry* **271**:15292–15297
10. Zhang X. Q., Ibrahimi O. A., Olsen S. K., Umemori H., Mohammadi M., Ornitz D. M. (2006) **Receptor specificity of the fibroblast growth factor family - The complete mammalian FGF family** *Journal of Biological Chemistry* **281**:15694–15700
11. Buchtova M., Chaloupkova R., Zakrzewska M., Vesela I., Cela P., Barathova J., Gudernova I., Zajickova R., Trantirek L., Martin J., Kostas M., Otlewski J., Damborsky J., Kozubik A., Wiedlocha A., Krejci P. (2015) **Instability restricts signaling of multiple fibroblast growth factors** *Cellular and Molecular Life Sciences* **72**:2445–2459
12. Passos-Bueno M. R., Sertie A. L., Richieri-Costa A., Alonso L. G., Zatz M., Alonso N., Brunoni D., Ribeiro S. F. M. (1998) **Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses** *American Journal of Medical Genetics* **78**:237–241
13. Wilkie A. O. M (2005) **Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations** *Cytokine & Growth Factor Reviews* **16**:187–203
14. White K. E., Cabral J. M., Davis S. I., Fishburn T., Evans W. E., Ichikawa S., Fields J., Yu X. J., Shaw N. J., McLellan N. J., McKeown C., FitzPatrick D., Yu K., Ornitz D. M., Econs M. J. (2005) **Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation** *American Journal of Human Genetics* **76**:361–367

15. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M. A., Natrajan R., Marchio C., Iorns E., Mackay A., Gillett C., Grigoriadis A., Tutt A., Reis J. S., Ashworth A. (2010) **FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer** *Cancer Research* **70**:2085–2094
16. Seo A. N., Jin Y., Lee H. J., Sun P. L., Kim H., Jheon S., Kim K., Lee C. T., Chung J. H. (2014) **FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer** *Virchows Archiv* **465**:547–558
17. Mariani F. V., Martin G. R. (2003) **Deciphering skeletal patterning: clues from the limb** *Nature* **423**:319–325
18. Tabin C., Wolpert L. (2007) **Rethinking the proximodistal axis of the vertebrate limb in the molecular era** *Genes Dev* **21**:1433–1442
19. Mariani F. V., Ahn C. P., Martin G. R. (2008) **Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning** *Nature* **453**:401–U456
20. Fafilek B., Balek L., Bosakova M. K., Varecha M., Nita A., Gregor T., Gudernova I., Krenova J., Ghosh S., Piskacek M., Jonatova L., Cernohorsky N. H., Zieba J. T., Kostas M., Haugsten E. M., Wesche J., Erneux C., Trantirek L., Krakow D., Krejci P. (2018) **The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases** *Sci Signal* **11**
21. Kimura T., Bosakova M., Nonaka Y., Hrubá E., Yasuda K., Futakawa S., Kubota T., Fafilek B., Gregor T., Abraham S. P., Gomolkova R., Belaskova S., Pesl M., Csukasi F., Duran I., Fujiwara M., Kavkova M., Zikmund T., Kaiser J., Buchtova M., Krakow D., Nakamura Y., Ozono K., Krejci P. (2021) **An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice** *Sci Transl Med* **13**
22. Gudernova I., Foldynova-Trantirkova S., Ghannamova B. E., Fafilek B., Varecha M., Balek L., Hrubá E., Jonatova L., Jelinkova I., Kunova Bosakova M., Trantirek L., Mayer J., Krejci P. (2017) **One reporter for in-cell activity profiling of majority of protein kinase oncogenes** *Elife* **6**
23. Needham S. R., Roberts S. K., Arkhipov A., Mysore V. P., Tynan C. J., Zanetti-Domingues L. C., Kim E. T., Losasso V., Korovesis D., Hirsch M., Rolfe D. J., Clarke D. T., Winn M. D., Lajevardipour A., Clayton A. H., Pike L. J., Perani M., Parker P. J., Shan Y., Shaw D. E., Martin-Fernandez M. L. (2016) **EGFR oligomerization organizes kinase-active dimers into competent signalling platforms** *Nat Commun* **7**
24. Singh D. R., Kanvinde P., King C., Pasquale E. B., Hristova K. (2018) **The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures** *Communications Biology* **1**
25. Sarabipour S., Hristova K. (2016) **Mechanism of FGF receptor dimerization and activation** *Nat. Commun* **7**
26. Stoneman M. R., Biener G., Ward R. J., Pediani J. D., Badu D., Eis A., Popa I., Milligan G., Raicu V. (2019) **A general method to quantify ligand-driven oligomerization from fluorescence-based images** *Nat Methods* **16**:493–496
27. Digman M. A., Gratton E. (2012) **Scanning image correlation spectroscopy** *BioEssays* **34**:377–385

28. Paul M. D., Rainwater R., Zuo Y., Gu L., Hristova K. (2021) **Probing Membrane Protein Association Using Concentration-Dependent Number and Brightness** *Angew Chem Int Ed Engl* **60**:6503–6508
29. Paul M. D., Grubb H. N., Hristova K. (2020) **Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling** *The Journal of biological chemistry* **295**:9917–9933
30. Ahmed F., Zapata-Mercado E., Rahman S., Hristova K. (2021) **The Biased Ligands NGF and NT-3 Differentially Stabilize Trk-A Dimers** *Biophys J* **120**:55–63
31. Moscatelli D (1987) **High and Low Affinity Binding-Sites for Basic Fibroblast Growth-Factor on Cultured-Cells - Absence of A Role for Low Affinity Binding in the Stimulation of Plasminogen-Activator Production by Bovine Capillary Endothelial-Cells** *Journal of Cellular Physiology* **131**:123–130
32. Roghani M., Mansukhani A., Dell’Era P., Bellosta P., Basilico C., Rifkin D. B., Moscatelli D. (1994) **Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding** *The Journal of biological chemistry* **269**:3976–3984
33. Gleizes P. E., Noaillac-Depeyre J., Amalric F., Gas N. (1995) **Basic fibroblast growth factor (FGF-2) internalization through the heparan sulfate proteoglycans-mediated pathway: an ultrastructural approach** *Eur J Cell Biol* **66**:47–59
34. Seiradake E., Schaupp A., Ruiz D. D. T., Kaufmann R., Mitakidis N., Harlos K., Aricescu A. R., Klein R., Jones E. Y. (2013) **Structurally encoded intraclass differences in EphA clusters drive distinct cell responses** *Nature Structural & Molecular Biology* **20**
35. Seiradake E., Harlos K., Sutton G., Aricescu A. R., Jones E. Y. (2010) **An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly** *Nature Structural & Molecular Biology* **17**:398–U327
36. Nikolov D. B., Xu K., Himanen J. P. (2014) **Homotypic receptor-receptor interactions regulating Eph signaling** *Cell Adhesion & Migration* **8**:360–365
37. Anderson D., Sweeney D. J., Williams T. A., Camm J. D., Cochran J. J. (2001) **Modern Business Statistics with Microsoft Excel**
38. Furdui C. M., Lew E. D., Schlessinger J., Anderson K. S. (2006) **Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction** *Molecular Cell* **21**:711–717
39. Lew E. D., Furdui C. M., Anderson K. S., Schlessinger J. (2009) **The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations** *Science Signaling*
40. Sorokin A., Mohammadi M., Huang J., Schlessinger J. (1994) **Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766** *The Journal of biological chemistry* **269**:17056–17061
41. Burgar H. R., Burns H. D., Elsdon J. L., Lalioti M. D., Heath J. K. (2002) **Association of the signaling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain** *The Journal of biological chemistry* **277**:4018–4023

42. Gotoh N (2008) **Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins** *Cancer Sci* **99**:1319–1325
43. Huang Z. F., Marsiglia W. M., Roy U. B., Rahimi N., Ilghari D., Wang H. Y., Chen H. B., Gai W. M., Blais S., Neubert T. A., Mansukhani A., Traaseth N. J., Li X. K., Mohammadi M. (2016) **Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase C gamma** *Molecular Cell* **61**:98–110
44. Rajagopal S., Ahn S., Rominger D. H., Gowen-MacDonald W., Lam C. M., Dewire S. M., Violin J. D., Lefkowitz R. J. (2011) **Quantifying ligand bias at seven-transmembrane receptors** *Mol Pharmacol* **80**:367–377
45. Kenakin T., Christopoulos A. (2013) **Measurements of ligand bias and functional affinity** *Nat Rev Drug Discov* **12**
46. Kenakin T (2016) **Measurement of Receptor Signaling Bias** *Curr Protoc Pharmacol* **74**
47. Gundry J., Glenn R., Alagesan P., Rajagopal S. (2017) **A Practical Guide to Approaching Biased Agonism at G Protein Coupled Receptors** *Front Neurosci* **11**
48. Kenakin T (2019) **Biased Receptor Signaling in Drug Discovery** *Pharmacol Rev* **71**:267–315
49. Ehlert F. J (2018) **Analysis of Biased Agonism** *Prog Mol Biol Transl Sci* **160**:63–104
50. Freed D. M., Bessman N. J., Kiyatkin A., Salazar-Cavazos E., Byrne P. O., Moore J. O., Valley C. C., Ferguson K. M., Leahy D. J., Lidke D. S., Lemmon M. A. (2017) **EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics** *Cell* **171**:683–695
51. Kiyatkin A., van Alderwerelt van Rosenburgh I. K., Klein D. E., Lemmon M. A. (2020) **Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics** *Sci Signal* **13**
52. Suwanmajo T., Krishnan J. (2013) **Biphasic responses in multi-site phosphorylation systems** *J R Soc Interface* **10**
53. Lax I., Wong A., Lamothe B., Lee A., Frost A., Hawes J., Schlessinger J. (2002) **The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors** *Mol Cell* **10**:709–719
54. Xie Y., Su N., Yang J., Tan Q., Huang S., Jin M., Ni Z., Zhang B., Zhang D., Luo F., Chen H., Sun X., Feng J. Q., Qi H., Chen L. (2020) **FGF/FGFR signaling in health and disease** *Signal Transduct Target Ther* **5**
55. Xian W., Schwertfeger K. L., Rosen J. M. (2007) **Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition** *Mol Endocrinol* **21**:987–1000
56. Fafulek B., Hampl M., Ricankova N., Vesela I., Balek L., Kunova Bosakova M., Gudernova I., Varecha M., Buchtova M., Krejci P. (2017) **Statins do not inhibit the FGFR signaling in chondrocytes** *Osteoarthritis Cartilage* **25**:1522–1530
57. Krejci P., Prochazkova J., Smutny J., Chlebova K., Lin P., Aklian A., Bryja V., Kozubik A., Wilcox W. R. (2010) **FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence** *Bone* **47**:102–110

58. Sarabipour S., Ballmer-Hofer K., Hristova K. (2016) **VEGFR-2 conformational switch in response to ligand binding** *Elife* **5**
59. Doerner A., Scheck R., Schepartz A. (2015) **Growth Factor Identity Is Encoded by Discrete Coiled-Coil Rotamers in the EGFR Juxtamembrane Region.** *Chem.Biol* :776–784
60. Ong S. H., Guy G. R., Hadari Y. R., Laks S., Gotoh N., Schlessinger J., Lax I. (2000) **FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors** *Mol Cell Biol* **20**:979–989
61. Scheck R. A., Lowder M. A., Appelbaum J. S., Schepartz A. (2012) **Bipartite tetracysteine display reveals allosteric control of ligand-specific EGFR activation** *ACS Chem Biol* **7**:1367–1376
62. Sarabipour S., Del Piccolo N., Hristova K. (2015) **Characterization of Membrane Protein Interactions in Plasma Membrane Derived Vesicles with Quantitative Imaging Forster Resonance Energy Transfer** *Acc.Chem.Res* **48**:2262–2269
63. King C., Stoneman M., Raicu V., Hristova K. (2016) **Fully quantified spectral imaging reveals in vivo membrane protein interactions** *Integr.Biol.(Camb)* **8**:216–229
64. Chen L. R., Novicky L., Merzlyakov M., Hristov T., Hristova K. (2010) **Measuring the Energetics of Membrane Protein Dimerization in Mammalian Membranes** *Journal of the American Chemical Society* **132**:3628–3635
65. Kozakov D., Hall D. R., Xia B., Porter K. A., Padhorny D., Yueh C., Beglov D., Vajda S. (2017) **The ClusPro web server for protein-protein docking** *Nat Protoc* **12**:255–278
66. Desta I. T., Porter K. A., Xia B., Kozakov D., Vajda S. (2020) **Performance and Its Limits in Rigid Body Protein-Protein Docking** *Structure* **28**:1071–1081
67. Chaudhury S., Lyskov S., Gray J. J. (2010) **PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta** *Bioinformatics* **26**:689–691
68. Karl K., Paul M. D., Pasquale E. B., Hristova K. (2020) **Ligand bias in receptor tyrosine kinase signaling** *The Journal of biological chemistry* **295**:18494–18507
69. Smith J. S., Lefkowitz R. J., Rajagopal S. (2018) **Biased signalling: from simple switches to allosteric microprocessors** *Nat Rev Drug Discov* **17**:243–260
70. Raucci A., Laplantine E., Mansukhani A., Basilico C. (2004) **Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes** *J Biol Chem* **279**:1747–1756
71. Priore R., Dailey L., Basilico C. (2006) **Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes** *J Cell Physiol* **207**:800–808
72. Kamemura N., Murakami S., Komatsu H., Sawanoi M., Miyamoto K., Ishidoh K., Kishimoto K., Tsuji A., Yuasa K. (2017) **Type II cGMP-dependent protein kinase negatively regulates fibroblast growth factor signaling by phosphorylating Raf-1 at serine 43 in rat chondrosarcoma cells** *Biochem Biophys Res Commun* **483**:82–87

73. Kolupaeva V., Daempfling L., Basilico C. (2013) **The B55alpha regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes** *Mol Cell Biol* **33**:2865–2878
74. Dailey L., Laplantine E., Priore R., Basilico C. (2003) **A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation** *J Cell Biol* **161**:1053–1066
75. Rozenblatt-Rosen O., Mosonogo-Ornan E., Sadot E., Madar-Shapiro L., Sheinin Y., Ginsberg D., Yayon A. (2002) **Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations** *Journal of Cell Science* **115**:553–562
76. Wendt D. J., Dvorak-Ewell M., Bullens S., Lorget F., Bell S. M., Peng J., Castillo S., Aoyagi-Scharber M., O'Neill C. A., Krejci P., Wilcox W. R., Rimoin D. L., Bunting S. (2015) **Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism** *J Pharmacol Exp Ther* **353**:132–149
77. Matsushita M., Kitoh H., Ohkawara B., Mishima K., Kaneko H., Ito M., Masuda A., Ishiguro N., Ohno K. (2013) **Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia** *PLoS One* **8**
78. Hadari Y. R., Kouhara H., Lax I., Schlessinger J. (1998) **Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation** *Molecular and Cellular Biology* **18**:3966–3973
79. Mi L. Z., Lu C., Li Z., Nishida N., Walz T., Springer T. A. (2011) **Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor** *Nat Struct Mol Biol* **18**:984–989
80. Opatowsky Y., Lax I., Tome F., Bleichert F., Unger V. M., Schlessinger J. (2014) **Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers** *Proc Natl Acad Sci U S A* **111**:1772–1777
81. Karl K., Hristova K. (2021) **Pondering the mechanism of receptor tyrosine kinase activation: The case for ligand-specific dimer microstate ensembles** *Curr Opin Struct Biol* **71**:193–199
82. Wilson K. J., Gilmore J. L., Foley J., Lemmon M. A., Riese D. J. (2009) **Functional selectivity of EGF family peptide growth factors: Implications for cancer** *Pharmacology & Therapeutics* **122**:1–8
83. Lu C., Mi L. Z., Grey M. J., Zhu J., Graef E., Yokoyama S., Springer T. A. (2010) **Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor** *Mol Cell Biol* **30**:5432–5443
84. Bocharov E. V., Mineev K. S., Pavlov K. V., Akimov S. A., Kuznetsov A. S., Efremov R. G., Arseniev A. S. (2017) **Helix-helix interactions in membrane domains of bitopic proteins: Specificity and role of lipid environment** *Biochim Biophys Acta* **1859**:561–576
85. Wykosky J., Palma E., Gibo D. M., Ringler S., Turner C. P., Debinski W. (2008) **Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor** *Oncogene* **27**:7260–7273

86. Gomez-Soler M., Petersen Gehring M., Lechtenberg B. C., Zapata-Mercado E., Hristova K., Pasquale E. B. (2019) **Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling** *The Journal of biological chemistry* **294**:8791–8805
87. Mohammadi M., Olsen S. K., Ibrahimi O. A. (2005) **Structural basis for fibroblast growth factor receptor activation** *Cytokine & Growth Factor Reviews* **16**:107–137
88. Needham S. R., Roberts S. K., Arkhipov A., Mysore V. P., Tynan C. J., Zanetti-Domingues L. C., Kim E. T., Losasso V., Korovesis D., Hirsch M., Rolfe D. J., Clarke D. T., Winn M. D., Lajevardipour A., Clayton A. H., Pike L. J., Perani M., Parker P. J., Shan Y., Shaw D. E., Martin-Fernandez M. L. (2016) **EGFR oligomerization organizes kinase-active dimers into competent signalling platforms** *Nat Commun* **7**
89. Huang Y., Bharill S., Karandur D., Peterson S. M., Marita M., Shi X., Kaliszewski M. J., Smith A. W., Isacoff E. Y., Kuriyan J. (2016) **Molecular basis for multimerization in the activation of the epidermal growth factor receptor** *Elife* **5**
90. Luttrell L. M (2014) **Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery** *Mol Endocrinol* **28**:281–294
91. Correll C. C., McKittrick B. A. (2014) **Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery** *J Med Chem* **57**:6887–6896
92. Kenakin T (2011) **Functional selectivity and biased receptor signaling** *J Pharmacol Exp Ther* **336**:296–302
93. Robertson S. C., Tynan J. A., Donoghue D. J. (2000) **RTK mutations and human syndromes - when good receptors turn bad** *Trends in Genetics* **16**:265–271
94. Browne B. C, O'Brien N., Duffy M. J., Crown J., O'Donovan N. (2009) **HER-2 Signaling and Inhibition in Breast Cancer. Current Cancer Drug Targets** :419–438
95. Li E., Hristova K. (2006) **Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies** *Biochemistry* **45**:6241–6251
96. Le X., Nilsson M., Goldman J., Reck M., Nakagawa K., Kato T., Ares L. P., Frimodt-Moller B., Wolff K., Visseren-Grul C., Heymach J. V., Garon E. B. (2021) **Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC** *J Thorac Oncol* **16**:205–215
97. Kumar R., George B., Campbell M. R., Verma N., Paul A. M., Melo-Alvim C., Ribeiro L., Pillai M. R., da Costa L. M., Moasser M. M. (2020) **HER family in cancer progression: From discovery to 2020 and beyond** *Adv Cancer Res* **147**:109–160
98. Hughes I. G., Hase T. (2010) **Hughes, I. G., and T. Hase. 2010. Measurements and their Uncertainties: A practical guide to modern error analysis.** *Measurements and their Uncertainties: A practical guide to modern error analysis*
99. Del Piccolo N., Placone J., He L., Agudelo S. C., Hristova K. (2012) **Production of plasma membrane vesicles with chloride salts and their utility as a cell membrane mimetic for biophysical characterization of membrane protein interactions** *Analytical Chemistry* **84**:8650–8655
100. Chen L., Placone J., Novicky L., Hristova K. (2010) **The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization** *Science Signaling* **3**

101. Rauch C., Farge E. (2000) **Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry** *Biophys J* **78**:3036–3047
102. Sinha B., Koster D., Ruez R., Gonnord P., Bastiani M., Abankwa D., Stan R. V., Butler-Browne G., Védie B., Johannes L., Morone N., Parton R. G., Raposo G., Sens P., Lamaze C., Nassoy P. (2011) **Cells respond to mechanical stress by rapid disassembly of caveolae** *Cell* **144**:402–413
103. Alford R. F., Leaver-Fay A., Jeliazkov J. R., O’Meara M. J., DiMaio F. P., Park H., Shapovalov M. V., Renfrew P. D., Mulligan V. K., Kappel K., Labonte J. W., Pacella M. S., Bonneau R., Bradley P., Dunbrack R. L., Das R., Baker D., Kuhlman B., Kortemme T., Gray J. J. (2017) **The Rosetta All-Atom Energy Function for Macromolecular Modeling and Design** *J Chem Theory Comput* **13**:3031–3048

Author information

Kelly Karl

Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University, Baltimore MD 21218
ORCID iD: [0000-0002-7810-3179](https://orcid.org/0000-0002-7810-3179)

Nuala Del Piccolo

Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University, Baltimore MD 21218
ORCID iD: [0000-0002-5104-7322](https://orcid.org/0000-0002-5104-7322)

Taylor Light

Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University, Baltimore MD 21218

Tanaya Roy

Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University, Baltimore MD 21218

Pooja Dudeja

Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic, International Clinical Research Center, St. Anne’s University Hospital, 65691 Brno, Czech Republic

Vlad-Constantin Ursachi

Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic, International Clinical Research Center, St. Anne’s University Hospital, 65691 Brno, Czech Republic

Bohumil Fafílek

Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic, Institute of Animal Physiology and Genetics of the CAS, 60200 Brno, Czech Republic, International Clinical Research Center, St. Anne’s University Hospital, 65691 Brno, Czech Republic

Pavel Krejci

Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic,
Institute of Animal Physiology and Genetics of the CAS, 60200 Brno, Czech Republic,
International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech
Republic
ORCID iD: [0000-0003-0618-9134](https://orcid.org/0000-0003-0618-9134)

Kalina Hristova

Department of Materials Science and Engineering, Institute for NanoBioTechnology, and
Program in Molecular Biophysics, Johns Hopkins University, Baltimore MD 21218
For correspondence: kalina.hristova@jhu.edu
ORCID iD: [0000-0003-4274-4406](https://orcid.org/0000-0003-4274-4406)

Editors

Reviewing Editor

Volker Dötsch

Goethe University, Germany

Senior Editor

Volker Dötsch

Goethe University, Germany

Joint Public Review

In this manuscript, Karl et al. explore mechanisms underlying the activation of the receptor tyrosine kinase FGFR1 and stimulation of intracellular signaling pathways in response to FGF4, FGF8, or FGF9 binding to the extracellular domain of FGFR1. Quantitative binding experiments presented in the manuscript demonstrate that FGF4, FGF8, and FGF9 exhibit distinct binding affinities towards FGFRs. It is also proposed that FGF8 exhibits "biased ligand" characteristics that is manifested via binding and activation FGFR1 mediated by "structural differences in the FGF- FGFR1 dimers, which impact the interactions of the FGFR1 trans membrane helices, leading to differential recruitment and activation of the downstream signaling adapter FRS2".

In the absence of any structural experimental data of different forms of FGFR dimers stimulated by FGF ligands the model presents in the manuscript is speculative and misleading.

Author Response

The following is the authors' response to the original reviews.

In response to the eLife assessment that "the analysis of the data is inadequate", we strongly disagree and we to point out that in fact we follow the latest IUPHAR community guidelines on bias identification and quantification (Kolb et al, 2022). These protocols are not yet being used in the RTK and FGF fields, and thus the reviewer is not familiar with them, or with the concept of ligand bias. Our responses to the technical comments start at the bottom of page 7 of this document.

We have edited the paper by adding a scaling step-by-step protocol in the Supplementary Data. We have also expanded the Discussion to help readers understand what is measured and how it is very novel. We have also changed the title of the manuscript. The edits in the Manuscript are marked in yellow. Our response to the reviewer is given below.

Question/comment: 1. Previous studies have demonstrated that the variability of signal transduction stimulated by different FGF family members originates from their preferential activation of different members of the FGFR family (Ornitz et al., 1996). For example, it was previously shown that members of the FGF8 subfamily preferentially activate FGFR3c, whereas members of the FGF4 subfamily activate FGFR1c more potently than other FGFs. Moreover, it was shown that FGF18, a member of the FGF8 subfamily, preferentially binds to and activates the FGFR3c isoform. Indeed, this can be seen in the data shown in Figure 3 in this manuscript, where maximum levels of FGFR1 pY653/4 and pFRS2 are reached at different concentrations when stimulated with increasing concentrations of each ligand in HEK293T cells.

The reviewer is correct that there are differences in the signaling of the different FGFRs, however these differences are not relevant for this work. This paper is only about FGFR1c, as this is the only FGF-receptor which is expressed in the mesenchyme of the developing limb bud (early limb bud stage, before the onset of mesenchymal condensations) and encounters different FGF ligands. In the article, we analyze the mechanism by which one FGFR recognizes and responds to three different FGFs.

The reviewer also correctly points out that differences in our work “can be seen in the data shown in Figure 3 in this manuscript, where maximum levels of FGFR1 pY653/4 and pFRS2 are reached at different concentrations when stimulated with increasing concentrations of each ligand in HEK293T cells”. This is correct, but this is a statement about the potencies of the ligands, which is just one of three characteristics we explore here, namely potencies, efficacies, and bias. To determine if ligand bias exists or not, we need to compare two ligands and two responses (such as growth arrest and ECM degradation, or pY653/4 and pFRS2 phosphorylation). Ours is the first report of ligand bias in FGFR1 signaling, and the presence of bias goes far beyond simply differences in potencies (Kolb et al, 2022). Ligand bias in FGFR1 has never been demonstrated before. In part, this is because there have been no cell lines that give us the opportunity to compare two functional responses to FGF stimulus, via just one endogenously expressed FGFR variant. Notice that the paper that the reviewer is citing, (Ornitz et al., 1996), compares only 1 (one) type of response, when induced by different ligands, i.e. proliferation, and thus cannot answer the question if ligand bias exists or not. We have edited the Discussion to emphasize this fact. We have also changed the title.

Two studies meant to characterize FGF binding to the FGFRs (Ornitz et al., 1996; Zhang et al., 2006) have defined the main rules of the FGF-FGFR interaction, such as exclusivity of the FGF3 subfamily (FGF3, FGF7, FGF10) for the ‘b’ variants of the FGFR1 and FGFR2. These studies however do not measure ligand binding. These studies were carried-out in BAF/3 cells, where the transfected FGFRs are treated with exogenous FGFs, to cause cell proliferation. As such, the studies have several limitations. In BAF/3 cells, the cell proliferation is used as a surrogate for FGF binding on FGFR. The FGFRs activate cell proliferation via RAS-ERK MAP kinase pathway. However, many other pathways of downstream signaling are initiated by FGFRs, regulating cell differentiation, migration, metabolism and apoptosis, in biological contexts. Using single cellular response (cell proliferation) as a surrogate for FGF binding to their receptors will favor FGF ligands causing cell proliferation. FGFs which have preference for other responses will incorrectly appear weakly binding and weakly activating in BAF/3 cells. Further, an FGF ligand binding with high affinity to the receptor but inducing a lower proliferative response will be recognized as a less ‘preferential’ for the particular receptor in the BAF/3 assay. Second, the significant

diversity of signaling of 18 FGFs through seven FGFR variants in mammalian development suggests that many previously unappreciated nodules of FGF-FGFR signaling exist, including the recently discovered FGF signaling towards primary cilia, or interaction with insulin receptor system (Kunova Bosakova et al., 2019; Neugebauer et al., 2009; Nies et al., 2022). This diversity is not reflected in BAF/3 assay, which respond to FGFs with only one phenotype. This is why we have used the RCS cells in the manuscript. In RCS cells, at least two qualitatively different cell responses can be induced by the FGF signaling, making the cell model ideal for elucidating biased signaling.

The so called ‘binding preferences’ based on the Ornitz articles are not binding measurements and should not be used universally to describe the FGF interactions with FGFRs, because we do not know what the term really means, nor what is it based on; the molecular basis of the FGFR signaling BAF/3 is poorly characterized. In our article, we model the processes occurring in every developing mammalian limb, where three FGF ligands (FGF4, FGF8, FGF9), released by the ectoderm at the surface of the limb bud, signal to the underlying mesenchymal cell expressing just one FGF-receptor, the FGFR1c (Mariani and Martin, 2003; Tabin and Wolpert, 2007). Unlike the BAF/3 cells engineered to ectopically express one FGFR and treated by recombinant FGFs in the lab, all three FGFs are recognized by cells expressing FGFR1c, and each of the three FGFs delivers unique morphogenetic information. The mechanisms underlying differential signaling of multiple FGFs via one FGFR are poorly defined, as the term ‘preferential signaling’ does not provide mechanistic explanation. Our article is a step towards understanding the complex processes of FGF ligand recognition and response. In our article, we evaluate the potency, the efficacy, the FGF-induced FGFR1c oligomerization and downregulation, and conformation of the active FGFR1c dimers in response to FGF4, FGF8 and FGF9. We show that FGF4, FGF8, and FGF9 are biased ligands, and that bias can explain differences in FGF4, FGF8 and FGF9-mediated cellular responses in development.

References

- Kolb P, Kenakin T, Alexander SPH, Bermudez M, et al. Community guidelines for GPCR ligand bias: IUPHAR review 32. *Br J Pharmacol*. 2022;179, 3651-3674.
- Kunova Bosakova M, Nita A, Gregor T, Varecha M, et al. Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase. *Proc Natl Acad Sci U S A*. 2019;116(10):4316-4325.
- Mariani FV, Martin GR. Deciphering skeletal patterning: clues from the limb. *Nature*. 2003;423(6937):319-25.
- Nies VJM, Struik D, Liu S, Liu W, et al. Autocrine FGF1 signaling promotes glucose uptake in adipocytes. *Proc Natl Acad Sci U S A*. 2022;119(40):e2122382119.
- Neugebauer JM, Amack JD, Peterson AG, Bisgrove BW, Yost HJ. FGF signalling during embryo development regulates cilia length in diverse epithelia. *Nature*. 2009;458(7238):651-4.
- Ornitz DM, Xu J, Colvin JS, McEwen DG, et al. Receptor specificity of the fibroblast growth factor family. *J Biol Chem*. 1996;271(25):15292-7.
- Tabin C, Wolpert L. Rethinking the proximodistal axis of the vertebrate limb in the molecular era. *Genes Dev*. 2007;21(12):1433-42.
- Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem*. 2006;281(23):15694-700.

Question/comment: In order to be sure that the 'biased agonist' described in this manuscript for FGF8 binding is not caused by binding preference towards different FGFR members, the authors should present data comparing cell signaling via FGFR3c stimulated by FGF4, FGF8, and FGF9.

Here, we study signaling by FGFR1, which is the only receptor that is expressed in the mesenchyme of the developing limb bud. FGFR3 is not expressed there, and thus we do not study FGFR3 in this paper. FGFR3 is important regulator of skeletal development, but is not involved in the early stages like FGFR1. When the bones are formed, FGFR3 regulates chondrocyte proliferation and differentiation in the growth plate cartilage (Colvin et al., 1996). In fact, we are currently performing experiments with FGFR3 and multiple FGF ligands, and we see that it also engages in biased signaling. However, these FGFR3 studies have no relevance to the current work and will be published separately.

The so called 'binding preferences towards different FGFR members', based on the Ornitz articles (Ornitz et al., 1996; Zhang et al., 2006) provides no mechanistic explanation about differential FGF signaling via the activation of a single FGFR. Our article is a step forward towards the mechanism, by demonstration, for the first time, that 'ligand bias' may explain differential signaling by FGF4, FGF8 and FGF9 via FGFR1c.

References

- Colvin JS, Bohn BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nat Genet.* 1996;12(4):390-7.
- Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. *J Biol Chem.* 1996;271(25):15292-7.
- Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem.* 2006;281(23):15694-700.

Question/comment: 2. It is well-established that FGFR signaling by canonical FGF family members including FGF4, FGF8, and FGF9 is dependent on interactions of heparin or heparan sulfate proteoglycans (HSPG) to the ligand the receptors. Differential contributions of heparin to cell signaling mediated by FGF4, FGF8, and FGF9 binding and activation of different FGFRs expressed in RCS cells as this cell express endogenous HSPG molecules. This question should be addressed by comparing cell signaling via FGFRs ectopically expressed in BAF/3 cells (which do not possess endogenous FGFRs and HSPG) stimulated by FGF4, FGF8, and FGF9 in the absence or presence of different heparin concentrations. This approach has been applied many times in the past to explore and establish the role of heparin in control of ligand induced FGFR activation.

The work cannot be done with BAF/3 cells, since the topic of the study is ligand bias so we need to compare at least two measurable responses. In RCS cells, the two functional responses are growth arrest and extracellular matrix degradation. In BAF/3 cells, ligand stimulation leads to one single response: proliferation.

The HSPG and other sulphated proteoglycans work as low affinity FGF co-receptors. They stabilize the FGF secondary structure, present the FGFs to the FGFRs, and participate in FGFFGFR interactions (Yayon et al., 1991; Schlessinger et al., 2000; Zakrzewska et al., 2009). In the FGF field, the FGF-FGFR interaction is commonly supported by addition of exogenous heparin, which is highly sulphated glycosaminoglycan capable of full substitution of the cell-bound HSPGs in their function as low affinity FGF co-receptors.

Most cells produce proteoglycans, including BAF/3 cells. The analysis of expression of FGFR overexpressed in BAF/3 cells demonstrated that FGFR1, FGFR2 and FGFR3 migrate as proteins of approximately 130-150 kDa (Ornitz et al., 1996; Fig. 1A), which implies extensive glycosylation in Golgi. For instance, the full-length amino acid sequence for human FGFR3 is 806 residues, which on acrylamide gel migrates as a band of approximately 85 kDa; heavier FGFR3 variants are Golgi-glycosylated proteins. The treatment with de-glycosylation enzymes reduces the molecular weight to the one expected from the amino acid sequence.

To carry-out the BAF/3 experiment with FGF4, FGF8, and FGF9 in the absence or presence of different heparin concentrations, as the referee suggests, makes no sense. In BAF/3 cells, all FGF stimulations were done in the presence of 2 μ g/ml heparin (Ornitz et al., 1996; Zhang et al., 2006), because without heparin there would be no signaling. Even if the BAF/3 cells produce ample HSPGs, the heparin would still have to be used, because without it many of the FGFs would likely cause no response, regardless of the FGFR variant expressed. We and other have demonstrated, that most of the FGFs require stabilization by heparin to elicit signaling in cells expressing abundant amounts of HSPG (Buchtova et al., 2015; Chen et al., 2012).

Why should we compare the FGF signaling in BAF/3 transfected with FGFR1, with the RCS cells which express endogenous FGFR1? In RCS cells, several cellular phenotypes caused by FGF signaling can be easily detected and quantified, in comparison with BAF/3 cells, which only respond to the FGF signaling by proliferation. No bias in signaling can be established in cells with display only single type of response. The RCS cells used in our paper represent one of the most tractable cellular models of FGFR signaling. There are more than 40 articles exploring the mechanisms of FGF-FGFR signaling in RCS cells, including mechanisms of FGF signal transduction, FGF regulation of cell cycle, cell proliferation, differentiation, premature senescence, loss of extracellular matrix, interaction of FGF signaling with WNT, cytokine and natriuretic peptide signaling, and others (Rauci et al., 2004; Priore et al., 2006; Kamemura et al., 2017; Kolupaeva et al., 2013; Krejci et al., 2005; Krejci et al., 2007; Krejci et al., 2010; Dailey et al., 2003; Rozenblatt-Rosen et al., 2002; Fafulek et al., 2008). In addition, the three treatments to inhibit pathological FGFR signaling which are now in human trials (RBM007, meclozine) or FDA-approved (vosoritide), were initially developed in RCS cells, benefiting from the well characterized molecular mechanisms of FGF signaling (Krejci et al., 2005; Wendt et al., 2015; Kimura et al., 2021; Matsushita et al., 2013). In comparison with RCS cells, very little is known about the mechanisms of the FGF signaling in BAF/3 cells, as the BAF/3 proliferation assay is used mostly to evaluate FGFR agonists and antagonists (Yamada et al., 2020; Kamatkar et al., 2019; Motomura et al., 2008). We have edited this information to the revised Discussion.

References

- Buchtova M, Oralova V, Aklian A, Masek J, et al. Fibroblast growth factor and canonical WNT/ β catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage. *Biochim Biophys Acta*. 2015 May;1852(5):839-50.
- Buchtova M, Chaloupkova R, Zakrzewska M, Vesela I, et al. Instability restricts signaling of multiple fibroblast growth factors. *Cell Mol Life Sci*. 2015 Jun;72(12):2445-59.
- Chen G, Gulbranson DR, Yu P, Hou Z, Thomson JA. Thermal stability of fibroblast growth factor protein is a determinant factor in regulating self-renewal, differentiation, and reprogramming in human pluripotent stem cells. *Stem Cells*. 2012 Apr;30(4):623-30.
- Fafulek B, Balek L, Bosakova MK, Varecha M, et al. The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases. *Sci Signal*. 2018 Sep 18;11(548):eaap8608.

Kamemura N, Murakami S, Komatsu H, Sawanoi M, et al. Biochem Biophys Res Commun. 2017 Jan 29;483(1):82-87.

Kamatkar N, Levy M, Hébert JM. Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized. Mol Ther Nucleic Acids. 2019 Sep 6;17:530-539.

Kimura T, Bosakova M, Nonaka Y, Hrubá E, Yasuda K, et al. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice. Sci Transl Med. 2021 ;13(592):eaba4226.

Kolupaeva V, Daempfling L, Basilico C. The B55 α regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes. Mol Cell Biol. 2013 Aug;33(15):2865-78.

Krejci P, Masri B, Salazar L, Farrington-Rock C, et al. Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem. 2007;282(5):2929-36.

Krejci P, Masri B, Fontaine V, Mekikian PB, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005 Nov 1;118(Pt 21):5089-100.

Krejci P, Prochazkova J, Smutny J, Chlebova K, et al. FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone. 2010;47(1):102-10.

Matsushita M, Kitoh H, Ohkawara B, Mishima K, et al. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One. 2013;8(12):e81569.

Motomura K, Hagiwara A, Komi-Kuramochi A, Hanyu Y, et al. An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection. Biochim Biophys Acta. 2008 Dec;1780(12):1432-40.

Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271(25):15292-7.

Priore R, Dailey L, Basilico C. Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. J Cell Physiol. 2006 Jun;207(3):800-8.

Raucci A, Laplantine E, Mansukhani A, Basilico C. Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J Biol Chem. 2004;279(3):1747-56.

Robinson JW, Egbert JR, Davydova J, Schmidt H, et al. Dephosphorylation is the mechanism of fibroblast growth factor inhibition of guanylyl cyclase-B. Cell Signal. 2017;40:222229.

Rozenblatt-Rosen O, Mosonego-Ornan E, Sadot E, Madar-Shapiro L, et al. Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations. J Cell Sci. 2002 Feb 1;115(Pt 3):553-62.

Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000 Sep;6(3):743-50.

Wendt DJ, Dvorak-Ewell M, Bullens S, Lorget F, et al. Neutral endopeptidase-resistant Ctype natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. *J Pharmacol Exp Ther*. 2015 Apr;353(1):132-49.

Yamada R, Fukumoto R, Noyama C, Fujisawa A, et al. An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors. *J Cosmet Dermatol*. 2020 Feb;19(2):477-484.

Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. *Cell*. 1991 Feb 22;64(4):841-8.

Zakrzewska M, Wiedlocha A, Szlachcic A, Krowarsch D, et al. Increased protein stability of FGF1 can compensate for its reduced affinity for heparin. *J Biol Chem*. 2009 Sep 11;284(37):25388-403. doi: 10.1074/jbc.M109.001289.

Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem*. 2006;281(23):15694-700.

Question/comment: It is impossible to interpret the FGFR binding characteristics and cellular activates of FGF4, FGF8, and FGF9 in the absence of information about the role of heparin in their binding and activation.

We do not measure ligand binding to FGFR1 in this study. We record biological responses when we treat with FGF different ligands, and thus we measure the efficacy and the potency of each ligand to induce a response, and then we compare 2 ligands and 2 responses to determine if bias exists or not. We do not ask questions about the role of heparin, as it is always there no matter if we treat with FGF4, FGF8, or FGF9.

Why it is not possible to interpret our cellular data? In our article, the RCS cells were treated with FGFs in the presence of 1 µg/ml heparin, as clearly stated in Methods section. Using heparin at 1 or more µg/ml, to stabilize FGFs and negate the effect of endogenous HSPG, is a standard approach in the FGF field. This includes the two articles, which the whole field have used for more than 20 years as a basic reference for FGF-FGFR interactions (Ornitz et al., 1996; Zhang et al., 2006). In these studies, 2 µg/ml of heparin along with FGFs was used to treat BAF/3 cells; no experiments were conducted without heparin, as it does not make sense. Most likely, without heparin the obtained FGF-FGFR ‘preferences’ would, in fact, be the differences in FGF thermal stability, as we clearly demonstrate in our previous study (Buchtova et al., 2015). The latter article gives a detailed information about the role of heparin in the signaling of multiple FGFs in RCS cells.

References

Buchtova M, Chaloupkova R, Zakrzewska M, Vesela I, Cela P, Barathova J, Gudernova I, Zajickova R, Trantirek L, Martin J, Kostas M, Otlewski J, Damborsky J, Kozubik A, Wiedlocha A, Krejci P. Instability restricts signaling of multiple fibroblast growth factors. *Cell Mol Life Sci*. 2015 Jun;72(12):2445-59.

Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. *J Biol Chem*. 1996;271(25):15292-7.
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem*. 2006;281(23):15694-700.

Technical Comments/Answers

Question/comment: 3. It is not clear how some of the experimental data were analyzed. Blots in Figures 3A and 3B should include controls (total FGFR1 for pY653/4 and total FRS for pFRS2). How are the data shown in Figure 3C normalized? It does look like the level of phosphorylation was all normalized against the strongest signals irrespective of which ligand was used. Each data representing each ligand should be separately normalized.

The reviewer is correct that most often in the RTK literature “each data representing each ligand is separately normalized”. But this approach will eliminate all the information about ligand efficacies and about ligand bias; it will only yield information about the potencies. Here we are not only interested in the potencies, as we are also interested to determine if bias exists or not. As such, we follow scaling protocols that have been established and are currently recommended for ligand bias studies (Kolb et al, 2022).

One way to explain why the scaling that the reviewer is recommending is not correct for this work is to look at equation 2. What the reviewer is suggestion is to set all values of E_{top} to 1. In this case, the bias coefficient will depend only on the measured potencies, EC_{50} . But this contradicts the very definition of bias, as it is NOT a difference in potencies only. In the literature, differences in potencies are called “quantitative differences”, while ligand bias describes differences which are called “qualitative” or “fundamental” (Kenakin, 2019).

To eliminate confusion, we have added a scaling protocol to the Supplement of the paper.

References

Kolb P, Kenakin T, Alexander SPH, Bermudez M, et al. Community guidelines for GPCR ligand bias: IUPHAR review 32. *Br J Pharmacol*. 2022;179, 3651-3674.

Kenakin T. Biased Receptor Signaling in Drug Discovery. *Pharmacol Rev* 2019;71, 267315.

Question/comment: 4. In page 6, authors used the plot shown in Figure 3 for 'FGFR downregulation' to conclude that "the effect of FGF4 on FGFR1 downregulation is smaller when compared to the effects of FGF8 and FGF9. However, it is unclear how the data shown in the plot was normalized - none of the data seem to reach "1.0". Moreover, the plot seems to suggest that FGF4 can strongly downregulate FGFR as it can downregulate FGFR with higher potency.

The Western blots assessing FGFR1 expression are easy to scale, as the value in the absence of ligand is set to 1. The expression decreases as a function of the ligand concentration. We plot FGFR1 downregulation, so we subtract 1 from the scaled FGFR1 band intensities. The total amount of FGFR1 never becomes undetectable (i.e. zero), as the ligand concentration is increased. Thus, a value of 1 in the downregulation curve is never obtained.

We have added a protocol for this scaling in the Supplement.

Question/comment: 5. The structural basis of FGFR1 ligand bias and the different dimeric configurations and interactions between the kinase domain of FGFR1 dimers are not warranted (Figure 6). In the absence of any structural experimental data of different forms of FGFR dimers stimulated by FGF ligands the model presents in the manuscript is speculative and misleading.

This statement about Figure 6 is not fully correct because Figure 6A and B show experimental data. These are FRET experiments which show that the biased ligand, FGF8, induces different FGFR1 transmembrane domain conformation, as compared to FGF4 and FGF9.

The rest of the panels in Figure 6 show modeling using PyRosetta. These are indeed not experimental data, but to the best of our knowledge this is the very first time PyRosetta has

been used to predict kinase-kinase interfaces.